

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/072371 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2005/002522

(22) International Filing Date: 26 January 2005 (26.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/539,387	26 January 2004 (26.01.2004)	US
60/544,411	12 February 2004 (12.02.2004)	US
60/546,631	20 February 2004 (20.02.2004)	US
60/555,504	22 March 2004 (22.03.2004)	US
60/570,891	12 May 2004 (12.05.2004)	US
60/590,649	23 July 2004 (23.07.2004)	US
60/590,573	23 July 2004 (23.07.2004)	US
60/592,744	29 July 2004 (29.07.2004)	US
60/611,790	20 September 2004 (20.09.2004)	US
60/614,518	29 September 2004 (29.09.2004)	US
60/623,387	29 October 2004 (29.10.2004)	US
60/626,678	9 November 2004 (09.11.2004)	US
10/997,405	24 November 2004 (24.11.2004)	US
PCT/US04/03971	24 November 2004 (24.11.2004)	US
PCT/US04/40709	3 December 2004 (03.12.2004)	US
60/641,956	6 January 2005 (06.01.2005)	US
60/643,347	10 January 2005 (10.01.2005)	US
PCT/US05/00799	10 January 2005 (10.01.2005)	US

(71) Applicant (for all designated States except US): **NEOSE TECHNOLOGIES, INC.** [US/US]; 102 Witmer Road, Horsham, PA 19044 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEFREES, Shawn** [US/US]; 126 Filly Drive, North Wales, PA 19454 (US). **BOWE, Caryn** [US/US]; 276 Cherry Lane, Doylestown, PA 19044 (US).

(74) Agent: **MANN, Jeffry, S.**; Morgan, Lewis & Bockius LLP, 2 Palo Alto Square, 3000 El Camino Real, Suite 700, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF

(57) Abstract: The present invention provides sugars, nucleotide sugars, activated sugars that include one or more polymeric modifying moiety within their structure. The invention is exemplified by reference to linear and branched polymers, such as the water-soluble polymer poly(ethylene glycol).



WO 2005/072371 A2

BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 60/539,387, filed January 26, 2004; U.S. Provisional Patent Application No. 60/555,504, filed March 22, 2004; U.S. Provisional Patent Application No. 60/590,573, filed July 23, 2004; U.S. Provisional Patent Application No. 60/555,504, filed March 22, 2004; U.S. Patent Application No. 10/997,405, filed November 24, 2004; U.S. Provisional Patent Application 60/544,411, filed February 12, 2004; U.S. Provisional Patent Application 60/546,631, filed February 20, 2004; U.S. Provisional Patent Application May 12, 2004; U.S. Patent Application ((Unassigned), Attorney Docket No. 40853-01-5138US), filed January 10, 2005; PCT Application No. ((Unassigned), Attorney Docket No. 40853-01-5146WO), filed December 3, 2004; U.S. Provisional Patent Application No. 60/590,649, filed July 23, 2004; U.S. Provisional Patent Application No. 60/611,790, filed September 20, 2004; U.S. Provisional Patent Application No. 60/592,744, filed July 29, 2004; U.S. Provisional Patent Application No. 60/614,518, filed September 29, 2004; U.S. Provisional Patent Application No. 60/623,387, filed October 29, 2004; U.S. Provisional Patent Application No. 60/626,678, filed November 9, 2004; and U.S. Provisional Patent Application No. ((Unassigned), Attorney Docket No. 040853-01-5150), filed January 6, 2005, the disclosure of each of which is incorporated herein by reference in its entirety for all purposes.

BACKGROUND OF THE INVENTION

Field of the Invention

[0002] The present invention resides in the field of modified sugars and nucleotides thereof.

Background

[0003] Post-expression *in vitro* modification of peptides is an attractive strategy to remedy the deficiencies of methods that rely on controlling glycosylation by engineering expression systems; including both modification of glycan structures or introduction of glycans at novel sites. A comprehensive toolbox of recombinant eukaryotic glycosyltransferases is becoming available, making *in vitro* enzymatic synthesis of mammalian glycoconjugates with custom

designed glycosylation patterns and glycosyl structures possible. See, for example, U.S. Patent No. 5,876,980; 6,030,815; 5,728,554; 5,922,577; and WO/9831826; US2003180835; and WO 03/031464.

[0004] Enzyme-based syntheses have the advantages of regioselectivity and stereoselectivity. Moreover, enzymatic syntheses are performed using unprotected substrates. Three principal classes of enzymes are used in the synthesis of carbohydrates, glycosyltransferases (*e.g.*, sialyltransferases, oligosaccharyltransferases, N-acetylglucosaminyltransferases), and glycosidases. The glycosidases are further classified as exoglycosidases (*e.g.*, β -mannosidase, β -glucosidase), and endoglycosidases (*e.g.*, Endo-A, Endo-M). Each of these classes of enzymes has been successfully used synthetically to prepare carbohydrates. For a general review, *see*, Crout *et al.*, *Curr. Opin. Chem. Biol.* **2**: 98-111 (1998).

[0005] Glycosyltransferases modify the oligosaccharide structures on glycopeptides. Glycosyltransferases are effective for producing specific products with good stereochemical and regiochemical control. Glycosyltransferases have been used to prepare oligosaccharides and to modify terminal N- and O-linked carbohydrate structures, particularly on glycopeptides produced in mammalian cells. For example, the terminal oligosaccharides of glycopeptides have been completely sialylated and/or fucosylated to provide more consistent sugar structures, which improves glycopeptide pharmacodynamics and a variety of other biological properties. For example, β -1,4-galactosyltransferase was used to synthesize lactosamine, an illustration of the utility of glycosyltransferases in the synthesis of carbohydrates (*see, e.g.*, Wong *et al.*, *J. Org. Chem.* **47**: 5416-5418 (1982)). Moreover, numerous synthetic procedures have made use of α -sialyltransferases to transfer sialic acid from cytidine-5'-monophospho-N-acetylneuraminic acid to the 3-OH or 6-OH of galactose (*see, e.g.*, Kevin *et al.*, *Chem. Eur. J.* **2**: 1359-1362 (1996)). Fucosyltransferases are used in synthetic pathways to transfer a fucose unit from guanosine-5'-diphosphofucose to a specific hydroxyl of a saccharide acceptor. For example, Ichikawa prepared sialyl Lewis-X by a method that involves the fucosylation of sialylated lactosamine with a cloned fucosyltransferase (Ichikawa *et al.*, *J. Am. Chem. Soc.* **114**: 9283-9298 (1992)). For a discussion of recent advances in glycoconjugate synthesis for therapeutic use *see*, Koeller *et al.*, *Nature Biotechnology* **18**: 835-841 (2000). *See also*, U.S. Patent No. 5,876,980; 6,030,815; 5,728,554; 5,922,577; and WO/9831826.

[0006] In addition to manipulating the structure of glycosyl groups on polypeptides, interest

has developed in preparing glycopeptides that are modified with one or more non-saccharide modifying group, such as water soluble polymers. Poly(ethyleneglycol) ("PEG") is an exemplary polymer that has been conjugated to polypeptides. The use of PEG to derivatize peptide therapeutics has been demonstrated to reduce the immunogenicity of the peptides. For example, U.S. Pat. No. 4,179,337 (Davis *et al.*) discloses non-immunogenic polypeptides, such as enzymes and peptide hormones coupled to polyethylene glycol (PEG) or polypropylene glycol. Between 10 and 100 moles of polymer are used per mole polypeptide. Although the in vivo clearance time of the conjugate is prolonged relative to that of the polypeptide, only about 15% of the physiological activity is maintained. Thus, the prolonged circulation half-life is counterbalanced by the dramatic reduction in peptide potency.

[0007] The loss of peptide activity is directly attributable to the non-selective nature of the chemistries utilized to conjugate the water-soluble polymer. The principal mode of attachment of PEG, and its derivatives, to peptides is a non-specific bonding through a peptide amino acid residue. For example, U.S. Patent No. 4,088,538 discloses an enzymatically active polymer-enzyme conjugate of an enzyme covalently bound to PEG. Similarly, U.S. Patent No. 4,496,689 discloses a covalently attached complex of α -1 proteinase inhibitor with a polymer such as PEG. Abuchowski *et al.* (*J. Biol. Chem.* **252**: 3578 (1977)) discloses the covalent attachment of MPEG to an amine group of bovine serum albumin. U.S. Patent No. 4,414,147 discloses a method of rendering interferon less hydrophobic by conjugating it to an anhydride of a dicarboxylic acid, such as poly(ethylene succinic anhydride). PCT WO 87/00056 discloses conjugation of PEG and poly(oxyethylated) polyols to such proteins as interferon- β , interleukin-2 and immunotoxins. EP 154,316 discloses and claims chemically modified lymphokines, such as IL-2 containing PEG bonded directly to at least one primary amino group of the lymphokine. U.S. Patent No. 4,055,635 discloses pharmaceutical compositions of a water-soluble complex of a proteolytic enzyme linked covalently to a polymeric substance such as a polysaccharide.

[0008] Another mode of attaching PEG to peptides is through the non-specific oxidation of glycosyl residues on a glycopeptide. The oxidized sugar is utilized as a locus for attaching a PEG moiety to the peptide. For example M'Timkulu (WO 94/05332) discloses the use of an amino-PEG to add PEG to a glycoprotein. The glycosyl moieties are randomly oxidized to the corresponding aldehydes, which are subsequently coupled to the amino-PEG.

[0009] In each of the methods described above, poly(ethyleneglycol) is added in a random,


non-specific manner to reactive residues on a peptide backbone. For the production of therapeutic peptides, it is clearly desirable to utilize a derivitization strategy that results in the formation of a specifically labeled, readily characterizable, essentially homogeneous product. A promising route to preparing specifically labeled peptides is through the use of enzymes, such as glycosyltransferases to append a modified sugar moiety onto a peptide. The modified sugar moiety must function as a substrate for the glycosyltransferase and be appropriately activated. Hence, synthetic routes that provide facile access to activated modified sugars are desirable. The present invention provides such a route.

SUMMARY OF THE INVENTION

[0010] The present invention provides polymeric species, sugars and activated sugars conjugated to these polymeric species and nucleotide sugars that include these polymers. The polymeric species include both water-soluble and water-insoluble species. Moreover, the polymers are either branched- or straight-chain polymers. Exemplary sugar moieties include straight-chain and cyclic structures and aldoses and ketoses.


[0011] The polymeric modifying group can be attached at any position of the sugar moiety. In the discussion below, the invention is exemplified by reference to an embodiment in which the polymeric modifying group is attached to C-5 of a furanose or C-6 of a pyranose. Those of skill will appreciate that the focus of the discussion is for clarity of illustration, the polymeric moiety can be attached to other positions of both pyranoses and furanoses using the methods set forth herein and art-recognized methods.

[0012] In an exemplary embodiment, the invention provides a sugar or a sugar nucleotide that is conjugated to a polymer:



[0013] In Formulae I and II, R¹ is H, CH₂OR⁷, COOR⁷ or OR⁷, in which R⁷ represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl. R² is H, OH or


a moiety that includes a nucleotide. An exemplary R^2 species according to this embodiment has the formula:



in which R^8 is a nucleoside.

[0014] The symbols R^3 , R^4 , R^5 , R^6 and $R^{6'}$ independently represent H, substituted or unsubstituted alkyl, OR^9 , $NHC(O)R^{10}$. The index d is 0 or 1. R^9 and R^{10} are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid. At least one of R^3 , R^4 , R^5 , R^6 or $R^{6'}$ includes the polymeric modifying moiety *e.g.*, PEG. In an exemplary embodiment, R^6 and $R^{6'}$, together with the carbon to which they are attached are components of the side chain of sialic acid. In a further exemplary embodiment, this side chain is functionalized with the polymeric modifying moiety.

[0015] In an exemplary embodiment, the polymeric moiety is bound to the sugar core, generally through a heteroatom on the core, through a linker, L, as shown below:



R^{11} is the polymeric moiety and L is selected from a bond and a linking group. The index w represents an integer selected from 1-6, preferably 1-3 and more preferably 1-2. Exemplary linking groups include substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl moieties and sialic acid. An exemplary component of the linker is an acyl moiety.

[0016] When L is a bond it is formed between a reactive functional group on a precursor of R^{11} and a reactive functional group of complementary reactivity on a precursor of L. L can be in place on the saccharide core prior to reaction with R^{11} . Alternatively, R^{11} and L can be incorporated into a preformed cassette that is subsequently attached to the saccharide core. As set forth herein, the selection and preparation of precursors with appropriate reactive functional groups is within the ability of those skilled in the art. Moreover, coupling the precursors proceeds by chemistries that are well understood in the art.

[0017] In an exemplary embodiment L is a linking group that is formed from an amino acid, or small peptide (e.g., 1-4 amino acid residues) providing a modified sugar in which the polymeric modifying moiety is attached through a substituted alkyl linker. An exemplary linker is glycine.


[0018] In an exemplary embodiment, R⁶ includes the polymeric modifying moiety. In another exemplary embodiment, R⁶ includes both the polymeric modifying moiety and a linker, L, joining the modifying moiety to the remainder of the molecule.

[0019] In an exemplary embodiment, the polymeric modifying moiety is a branched structure that includes two or more polymeric chains attached to central moiety. An exemplary structure of a useful polymeric modifying moiety precursor according to this embodiment of the invention has the formula:



The sugars and nucleotide sugars according to this formula are essentially pure water-soluble polymers. X^{3'} is a moiety that includes an ionizable (e.g., COOH, etc.) or other reactive functional group, *see, e.g., infra*. C is carbon. X⁵ is preferably a non-reactive group (e.g., H, unsubstituted alkyl, unsubstituted heteroalkyl). R¹² and R¹³ are independently selected polymeric arms, e.g., nonpeptidic, nonreactive polymeric arms. X² and X⁴ are linkage fragments that are preferably essentially non-reactive under physiological conditions, which may be the same or different. Alternatively, these linkages can include one or more moiety that is designed to degrade under physiologically relevant conditions, e.g., esters, disulfides, etc. X² and X⁴ join polymeric arms R¹² and R¹³ to C. When X^{3'} is reacted with a reactive functional group of complementary reactivity on a linker, sugar or linker-sugar cassette, X^{3'} is converted to a component of linkage fragment X³.

[0020] By reaction of the precursor with a suitable sugar or sugar linker species the invention provides sugars and nucleotide sugars that have the formulae:




in which the identity of the radicals represented by the various symbols is the same as that discussed hereinabove. L^a is a substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl moiety. In an exemplary embodiment, L^a is a moiety of the side chain of sialic acid that is functionalized with the polymeric modifying moiety as shown.

[0021] The polymeric modifying moiety comprises two or more repeating units that can be water-soluble or essentially insoluble in water. Exemplary water-soluble polymers of use in the compounds of the invention include PEG, e.g., m-PEG, PPG, e.g., m-PPG, polysialic acid, polyglutamate, polyaspartate, polylysine, polyethyleneimine, biodegradable polymers (e.g., polylactide, polyglyceride), and functionalized PEG, e.g., terminal- functionized PEG.

[0022] The sugar moiety of the polymeric conjugates of the invention is selected from both natural and unnatural furanoses and hexanoses. The unnatural saccharides optionally include an alkylated or acylated hydroxyl and/or amine moiety, e.g., ethers, esters and amide substituents on the ring. Other unnatural saccharides include an H, hydroxyl, ether, ester or amide substituent at a position on the ring at which such a substituent is not present in the natural saccharide. Alternatively, the carbohydrate is missing a substituent that would be found in the carbohydrate from which its name is derived, e.g., deoxy sugars. Still further exemplary unnatural sugars include both oxidized (e.g., -onic and -uronic acids) and reduced (sugar alcohols) carbohydrates. The sugar moiety can be a mono-, oligo- or poly-saccharide.

[0023] Exemplary natural sugars of use in the present invention include glucose, glucosamine, galactose, galactosamine, fucose, mannose, mannosamine, xylanose, ribose, N-acetyl glucose, N-acetyl glucosamine, N-acetyl galactose, N-acetyl galactosamine, and sialic acid.

[0024] An exemplary sialic acid-based conjugate has the formula:



in which AA is that portion of an amino acid residue that does not include the carboxyl moiety and NP is a nucleotide phosphate. ONP can also be replaced by an activating moiety to form an activated sugar. As will be appreciated by those of skill in the art, the polymeric modifying moiety-linker can also be attached to the sialic acid side chain at C-6, C-7 and/or C-9.

[0025] Also provided is a synthetic method for producing an activated sialic acid-PEG conjugate that is an appropriate substrate for an enzyme, e.g., a glycosyltransferase. The method includes the steps: (a) contacting mannosamine with an activated, N-protected amino acid (or an amino acid functionalized with a polymeric modifying moiety, a linker precursor or a linker-polymeric modifying moiety cassette) under conditions appropriate to form an amide conjugate between the mannosamine and the N-protected amino acid; (b) contacting the amide conjugate with pyruvate and sialic acid aldolase under conditions appropriate to convert the amide conjugate to a sialic acid amide conjugate; (c) contacting the sialic acid amide conjugate with cytidine triphosphates, and a synthetase under conditions appropriate to form a cytidine monophosphate sialic acid amide conjugate; (d) removing the N-protecting group from the cytidine monophosphate sialic acid amide conjugate, thereby producing a free amine; and (e) contacting the free amine with an activated PEG (straight-chain or branched), thereby forming the cytidine monophosphate sialic acid-poly(ethylene glycol).

[0026] The nucleoside can be selected from both natural and unnatural nucleosides.

Exemplary natural nucleosides of use in the present invention include cytosine, thymine, guanine, adenine and uracil. The art is replete with structures of unnatural nucleosides and methods of making them.

[0027] Exemplary modified sugar nucleotides of the invention include polymerically-modified GDP-Man, GDP-Fuc, UDP-Gal, UDP-GalNAc, UDP-Glc, UDP-GlcNAc, UDP-Glc, UDP-GlcUA and CMP-SA and the like. Examples include UDP-Gal-2'-NH-PEG, UDP-Glc-2'-NH-PEG, CMP-5'-PEG-SA and the like. Compounds encompassed by the invention include those in which the L-R¹¹ moiety is conjugated to a furanose or a pyranose,

e.g., at C-5 of a furanose or at C-6 of a pyranose, generally through a heteroatom attached to this carbon atom.

[0028] When the compound of the invention is a nucleotide sugar, or activated sugar, the polymeric conjugates of the nucleotide sugars are generally substrates for an enzyme that transfers the sugar moiety and its polymeric substituent onto an appropriate acceptor moiety of a substrate. Accordingly, the invention also provides substrates modified by glycoconjugation using a polymeric conjugate of a nucleotide sugar, or activated sugar, and an appropriate enzyme. Substrates that can be glycoconjugated using a compound of the invention include peptides, e.g., glycopeptides, peptides, lipids, e.g., glycolipids and aglycones (sphingosines, ceramides).

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] **FIG. 1** is a table of sialyltransferases for which selected modified sialic acid nucleotides and activated sugars are substrates.

[0030] **FIG. 2** is a general synthetic scheme of the invention for preparing a sialic acid-poly(ethylene glycol) conjugate.

[0031] **FIG. 3** is a synthetic scheme of the invention for preparing a sialic acid-glycyl-poly(ethylene glycol) conjugate.

DETAILED DESCRIPTION OF THE INVENTION AND THE EMBODIMENTS

Abbreviations

[0032] Branched and unbranched PEG, poly(ethyleneglycol), e.g., m-PEG, methoxy-poly(ethylene glycol); Branched and unbranched PPG, poly(propyleneglycol), e.g., m-PPG, methoxy-poly(propylene glycol); Fuc, fucosyl; Gal, galactosyl; GalNAc, N-acetylgalactosaminyl; Glc, glucosyl; GlcNAc, N-acetylglucosaminyl; Man, mannosyl; ManAc, mannosaminyl acetate; Sia, sialic acid; and NeuAc, N-acetylneuraminyl.

Definitions

[0033] The term "sialic acid" refers to any member of a family of nine-carbon carboxylated sugars. The most common member of the sialic acid family is N-acetyl-neuraminic acid (2-

keto-5-acetamido-3,5-dideoxy-D-glycero-D-galactononulopyranos-1-onic acid (often abbreviated as Neu5Ac, NeuAc, or NANA). A second member of the family is N-glycolyl-neuraminic acid (Neu5Gc or NeuGc), in which the N-acetyl group of NeuAc is hydroxylated. A third sialic acid family member is 2-keto-3-deoxy-nonulosonic acid (KDN) (Nadano *et al.* (1986) *J. Biol. Chem.* **261**: 11550-11557; Kanamori *et al.*, *J. Biol. Chem.* **265**: 21811-21819 (1990)). Also included are 9-substituted sialic acids such as a 9-O-C₁-C₆ acyl-Neu5Ac like 9-O-lactyl-Neu5Ac or 9-O-acetyl-Neu5Ac, 9-deoxy-9-fluoro-Neu5Ac and 9-azido-9-deoxy-Neu5Ac. For review of the sialic acid family, *see, e.g.*, Varki, *Glycobiology* **2**: 25-40 (1992); *Sialic Acids: Chemistry, Metabolism and Function*, R. Schauer, Ed. (Springer-Verlag, New York (1992)). The synthesis and use of sialic acid compounds in a sialylation procedure is disclosed in international application WO 92/16640, published October 1, 1992.

[0034] As used herein, the term “modified sugar,” refers to a naturally- or non-naturally-occurring carbohydrate that is enzymatically added onto an amino acid or a glycosyl residue of a peptide in a process of the invention. The modified sugar is selected from a number of enzyme substrates including, but not limited to sugar nucleotides (mono-, di-, and tri-phosphates), activated sugars (*e.g.*, glycosyl halides, glycosyl mesylates) and sugars that are neither activated nor nucleotides. The “modified sugar” is covalently functionalized with a “modifying group.” Useful modifying groups include, but are not limited to, water-soluble polymers, therapeutic moieties, diagnostic moieties, biomolecules and the like. The modifying group is preferably not a naturally occurring, or an unmodified carbohydrate. The locus of functionalization with the modifying group is selected such that it does not prevent the “modified sugar” from being added enzymatically to a peptide.

[0035] The term “water-soluble” refers to moieties that have some detectable degree of solubility in water. Methods to detect and/or quantify water solubility are well known in the art. Exemplary water-soluble polymers include peptides, saccharides, poly(ethers), poly(amines), poly(carboxylic acids) and the like. Peptides can have mixed sequences or be composed of a single amino acid, *e.g.*, poly(lysine). An exemplary polysaccharide is poly(sialic acid). An exemplary poly(ether) is poly(ethylene glycol), *e.g.*, m-PEG. Poly(ethylene imine) is an exemplary polyamine, and poly(acrylic) acid is a representative poly(carboxylic acid). Exemplary polymers are typically comprised of 2-8 polymeric units.

[0036] The polymer backbone of the water-soluble polymer can be poly(ethylene glycol) (*i.e.* PEG). However, it should be understood that other related polymers are also suitable for use

in the practice of this invention and that the use of the term PEG or poly(ethylene glycol) is intended to be inclusive and not exclusive in this respect. The term PEG includes poly(ethylene glycol) in any of its forms, including alkoxy PEG, difunctional PEG, multiarmed PEG, forked PEG, branched PEG, pendent PEG (i.e. PEG or related polymers having one or more functional groups pendent to the polymer backbone), or PEG with degradable linkages therein.

[0037] The polymer backbone can be linear or branched. Branched polymer backbones are generally known in the art. Typically, a branched polymer has a central branch core moiety and a plurality of linear polymer chains linked to the central branch core. PEG is commonly used in branched forms that can be prepared by addition of ethylene oxide to various polyols, such as glycerol, pentaerythritol and sorbitol. The central branch moiety can also be derived from several amino acids, such as lysine. The branched poly(ethylene glycol) can be represented in general form as $R(-\text{PEG}-\text{OH})_m$ in which R represents the core moiety, such as glycerol or pentaerythritol, and m represents the number of arms. Multi-armed PEG molecules, such as those described in U.S. Pat. No. 5,932,462, which is incorporated by reference herein in its entirety, can also be used as the polymer backbone.

[0038] Many other polymers are also suitable for the invention. Polymer backbones that are non-peptidic and water-soluble, with from 2 to about 300 termini, are particularly useful in the invention. Examples of suitable polymers include, but are not limited to, other poly(alkylene glycols), such as poly(propylene glycol) ("PPG"), copolymers of ethylene glycol and propylene glycol and the like, poly(oxyethylated polyol), poly(olefinic alcohol), poly(vinylpyrrolidone), poly(hydroxypropylmethacrylamide), poly(α -hydroxy acid), poly(vinyl alcohol), polyphosphazene, polyoxazoline, poly(N-acryloylmorpholine), such as described in U.S. Pat. No. 5,629,384, which is incorporated by reference herein in its entirety, and copolymers, terpolymers, and mixtures thereof. Although the molecular weight of each chain of the polymer backbone can vary, it is typically in the range of from about 100 Da to about 100,000 Da, often from about 6,000 Da to about 80,000 Da.

[0039] The term "glycoconjugation," as used herein, refers to the enzymatically mediated conjugation of a modified sugar species to an amino acid or glycosyl residue of a polypeptide, *e.g.*, a mutant human growth hormone of the present invention. A subgenus of "glycoconjugation" is "glycol-PEGylation," in which the modifying group of the modified

sugar is poly(ethylene glycol), and alkyl derivative (*e.g.*, m-PEG) or reactive derivative (*e.g.*, H₂N-PEG, HOOC-PEG) thereof.

[0040] The term, “glycosyl linking group,” as used herein refers to a glycosyl residue to which a modifying group (*e.g.*, PEG moiety, therapeutic moiety, biomolecule) is covalently attached; the glycosyl linking group joins the modifying group to the remainder of the conjugate. In the methods of the invention, the “glycosyl linking group” becomes covalently attached to a glycosylated or unglycosylated peptide, thereby linking the agent to an amino acid and/or glycosyl residue on the peptide. A “glycosyl linking group” is generally derived from a “modified sugar” by the enzymatic attachment of the “modified sugar” to an amino acid and/or glycosyl residue of the peptide. The glycosyl linking group can be a saccharide-derived structure that is degraded during formation of modifying group-modified sugar cassette (*e.g.*, oxidation→Schiff base formation→reduction), or the glycosyl linking group may be intact. An “intact glycosyl linking group” refers to a linking group that is derived from a glycosyl moiety in which the saccharide monomer that links the modifying group and to the remainder of the conjugate is not degraded, *e.g.*, oxidized, *e.g.*, by sodium metaperiodate. “Intact glycosyl linking groups” of the invention may be derived from a naturally occurring oligosaccharide by addition of glycosyl unit(s) or removal of one or more glycosyl unit from a parent saccharide structure.

[0041] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, *e.g.*, -CH₂O- is intended to also recite -OCH₂-.

[0042] The term “alkyl,” by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (*i.e.* C₁-C₁₀ means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-

pentadienyl), ethynyl, 1- and 3-propynyl, 3-butyryl, and the higher homologs and isomers. The term “alkyl,” unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.” Alkyl groups that are limited to hydrocarbon groups are termed “homoalkyl”.

[0043] The term “alkylene” by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, and further includes those groups described below as “heteroalkylene.” Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.

[0044] The terms “alkoxy,” “alkylamino” and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.

[0045] The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, $-\text{CH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{CH}_2\text{NHCH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)\text{CH}_3$, $-\text{CH}_2\text{SCH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{S}(\text{O})\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{CH}_3$, $-\text{CH}=\text{CHOCH}_3$, $-\text{Si}(\text{CH}_3)_3$, $-\text{CH}_2\text{CH}=\text{NOCH}_3$, and $-\text{CH}=\text{CHN}(\text{CH}_3)\text{CH}_3$. Up to two heteroatoms may be consecutive, such as, for example, $-\text{CH}_2\text{NHCH}_3$ and $-\text{CH}_2\text{OSi}(\text{CH}_3)_3$. Similarly, the term “heteroalkylene” by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, $-\text{CH}_2\text{CH}_2\text{SCH}_2\text{CH}_2-$ and $-\text{CH}_2\text{SCH}_2\text{CH}_2\text{NHCH}_2-$. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (*e.g.*, alkyleneoxy, alkyleneedioxy, alkyleneamino, alkylene diamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula $-\text{C}(\text{O})_2\text{R}'$ represents both $-\text{C}(\text{O})_2\text{R}'$ and $-\text{R}'\text{C}(\text{O})_2-$.

[0046] The terms “cycloalkyl” and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1 – (1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 – piperazinyl, 2-piperazinyl, and the like.

[0047] The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C₁-C₄)alkyl” is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0048] The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently. The term “heteroaryl” refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxaliny, 5-quinoxaliny, 3-quinolyl, tetrazolyl, benzo[b]furanyl, benzo[b]thienyl, 2,3-dihydrobenzo[1,4]dioxin-6-yl, benzo[1,3]dioxol-5-yl and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

[0049] For brevity, the term “aryl” when used in combination with other terms (*e.g.*, aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the

term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (*e.g.*, benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (*e.g.*, a methylene group) has been replaced by, for example, an oxygen atom (*e.g.*, phenoxymethyl, 2-pyridyloxymethyl, 3-(1-naphthyloxy)propyl, and the like).

[0050] Each of the above terms (*e.g.*, "alkyl," "heteroalkyl," "aryl" and "heteroaryl") is meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0051] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are generically referred to as "alkyl group substituents," and they can be one or more of a variety of groups selected from, but not limited to: -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)₂R', -NR-C(NR'R''R''')=NR''', -NR-C(NR'R'')=NR'', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂ in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'', R''' and R'''' each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, *e.g.*, aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R'' is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (*e.g.*, -CF₃ and -CH₂CF₃) and acyl (*e.g.*, -C(O)CH₃, -C(O)CF₃, -C(O)CH₂OCH₃, and the like).

[0052] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are generically referred to as "aryl group substituents." The substituents are selected from, for example: halogen, -OR', =O, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R',

-NR'-C(O)NR''R''', -NR''C(O)₂R', -NR-C(NR'R''R''')=NR''''', -NR-C(NR'R'')=NR''''', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -NRSO₂R', -CN and -NO₂, -R', -N₃, -CH(Ph)₂, fluoro(C₁-C₄)alkoxy, and fluoro(C₁-C₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R'', R''' and R'''' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R'', R''' and R'''' groups when more than one of these groups is present. In the schemes that follow, the symbol X represents "R" as described above.

[0053] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR')_q-U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH₂)_r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)₂-, -S(O)₂NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR')_s-X-(CR''R''')_d-, where s and d are independently integers of from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)₂-, or -S(O)₂NR'-. The substituents R, R', R'' and R''' are preferably independently selected from hydrogen or substituted or unsubstituted (C₁-C₆)alkyl.

[0054] As used herein, the term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

[0055] The use of reactive derivatives of PEG (or other linkers) to attach one or more peptide moieties to the linker is within the scope of the present invention. The invention is not limited by the identity of the reactive PEG analogue. Many activated derivatives of poly(ethyleneglycol) are available commercially and in the literature. It is well within the abilities of one of skill to choose, and synthesize if necessary, an appropriate activated PEG derivative with which to prepare a substrate useful in the present invention. See, Abuchowski *et al. Cancer Biochem. Biophys.*, **7**: 175-186 (1984); Abuchowski *et al., J. Biol. Chem.*, **252**: 3582-3586 (1977); Jackson *et al., Anal. Biochem.*, **165**: 114-127 (1987); Koide *et al.*,

Biochem Biophys. Res. Commun., **111**: 659-667 (1983)), tresylate (Nilsson *et al.*, *Methods Enzymol.*, **104**: 56-69 (1984); Delgado *et al.*, *Biotechnol. Appl. Biochem.*, **12**: 119-128 (1990)); N-hydroxysuccinimide derived active esters (Buckmann *et al.*, *Makromol. Chem.*, **182**: 1379-1384 (1981); Joppich *et al.*, *Makromol. Chem.*, **180**: 1381-1384 (1979); Abuchowski *et al.*, *Cancer Biochem. Biophys.*, **7**: 175-186 (1984); Katre *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, **84**: 1487-1491 (1987); Kitamura *et al.*, *Cancer Res.*, **51**: 4310-4315 (1991); Boccu *et al.*, *Z. Naturforsch.*, **38C**: 94-99 (1983), carbonates (Zalipsky *et al.*, POLY(ETHYLENE GLYCOL) CHEMISTRY: BIOTECHNICAL AND BIOMEDICAL APPLICATIONS, Harris, Ed., Plenum Press, New York, 1992, pp. 347-370; Zalipsky *et al.*, *Biotechnol. Appl. Biochem.*, **15**: 100-114 (1992); Veronese *et al.*, *Appl. Biochem. Biotech.*, **11**: 141-152 (1985)), imidazolyl formates (Beauchamp *et al.*, *Anal. Biochem.*, **131**: 25-33 (1983); Berger *et al.*, *Blood*, **71**: 1641-1647 (1988)), 4-dithiopyridines (Woghiren *et al.*, *Bioconjugate Chem.*, **4**: 314-318 (1993)), isocyanates (Byun *et al.*, *ASAIO Journal*, M649-M-653 (1992)) and epoxides (U.S. Pat. No. 4,806,595, issued to Noishiki *et al.*, (1989). Other linking groups include the urethane linkage between amino groups and activated PEG. See, Veronese, *et al.*, *Appl. Biochem. Biotechnol.*, **11**: 141-152 (1985).

[0056] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, *e.g.*, hydroxyproline, γ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, *i.e.*, an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, *e.g.*, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (*e.g.*, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. "Amino acid mimetics" refers to chemical compounds having a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

[0057] "Peptide" refers to a polymer in which the monomers are amino acids, amino acid analogues and/or amino acid mimetics and are joined together through amide bonds, alternatively referred to as a polypeptide. Additionally, unnatural amino acids, for example, β -alanine, phenylglycine and homoarginine are also included. Amino acids that are not gene-

encoded may also be used in the present invention. Furthermore, amino acids that have been modified to include reactive groups, glycosylation sites, polymers, therapeutic moieties, biomolecules and the like may also be used in the invention. All of the amino acids used in the present invention may be either the D - or L -isomer. The L -isomer is generally preferred. In addition, other peptidomimetics are also useful in the present invention. As used herein, "peptide" refers to both glycosylated and unglycosylated peptides. Also included are peptides that are incompletely glycosylated by a system that expresses the peptide. For a general review, *see*, Spatola, A. F., in CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS, PEPTIDES AND PROTEINS, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983).

[0058] The term "nucleoside" refers to a glycosylamine that is a component of a nucleic acid and that comprises a nitrogenous base linked either to β -D-ribofuranose to form a ribonucleoside, or to 2-deoxy- β -D-ribofuranose to form a deoxyribonucleoside. The base may be a purine *e.g.*, adenine or guanosine, or a pyrimidine *e.g.*, thymidine, cytidine, uridine or pseudouridine. Nucleoside also includes the unusual nucleoside used by microorganisms.

[0059] The term "targeting moiety," as used herein, refers to species that will selectively localize in a particular tissue or region of the body. The localization is mediated by specific recognition of molecular determinants, molecular size of the targeting agent or conjugate, ionic interactions, hydrophobic interactions and the like. Other mechanisms of targeting an agent to a particular tissue or region are known to those of skill in the art. Exemplary targeting moieties include antibodies, antibody fragments, transferrin, HS-glycoprotein, coagulation factors, serum proteins, β -glycoprotein, G-CSF, GM-CSF, M-CSF, EPO and the like.

[0060] As used herein, "therapeutic moiety" means any agent useful for therapy including, but not limited to, antibiotics, anti-inflammatory agents, anti-tumor drugs, cytotoxins, and radioactive agents. "Therapeutic moiety" includes prodrugs of bioactive agents, constructs in which more than one therapeutic moiety is bound to a carrier, *e.g.*, multivalent agents. Therapeutic moiety also includes proteins and constructs that include proteins. Exemplary proteins include, but are not limited to, Erythropoietin (EPO), Granulocyte Colony Stimulating Factor (GCSF), Granulocyte Macrophage Colony Stimulating Factor (GMCSF), Interferon (*e.g.*, Interferon- α , - β , - γ), Interleukin (*e.g.*, Interleukin II), serum proteins (*e.g.*, Factors VII, VIIa, VIII, IX, and X), Human Chorionic Gonadotropin (HCG), Follicle

Stimulating Hormone (FSH) and Lutenizing Hormone (LH) and antibody fusion proteins (e.g. Tumor Necrosis Factor Receptor ((TNFR)/Fc domain fusion protein)).

[0061] As used herein, "anti-tumor drug" means any agent useful to combat cancer including, but not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, interferons and radioactive agents. Also encompassed within the scope of the term "anti-tumor drug," are conjugates of peptides with anti-tumor activity, *e.g.* TNF- α . Conjugates include, but are not limited to those formed between a therapeutic protein and a glycoprotein of the invention. A representative conjugate is that formed between PSGL-1 and TNF- α .

[0062] As used herein, "a cytotoxin or cytotoxic agent" means any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracinedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Other toxins include, for example, ricin, CC-1065 and analogues, the duocarmycins. Still other toxins include diphtheria toxin, and snake venom (*e.g.*, cobra venom).

[0063] As used herein, "a radioactive agent" includes any radioisotope that is effective in diagnosing or destroying a tumor. Examples include, but are not limited to, indium-111, cobalt-60. Additionally, naturally occurring radioactive elements such as uranium, radium, and thorium, which typically represent mixtures of radioisotopes, are suitable examples of a radioactive agent. The metal ions are typically chelated with an organic chelating moiety.

[0064] Many useful chelating groups, crown ethers, cryptands and the like are known in the art and can be incorporated into the compounds of the invention (*e.g.*, EDTA, DTPA, DOTA, NTA, HDTA, *etc.* and their phosphonate analogs such as DTPP, EDTP, HDTP, NTP, *etc.*). *See, for example, Pitt et al., "The Design of Chelating Agents for the Treatment of Iron Overload," In, INORGANIC CHEMISTRY IN BIOLOGY AND MEDICINE; Martell, Ed.; American Chemical Society, Washington, D.C., 1980, pp. 279-312; Lindoy, THE CHEMISTRY OF MACROCYCLIC LIGAND COMPLEXES; Cambridge University Press, Cambridge, 1989; Dugas,*

BIOORGANIC CHEMISTRY; Springer-Verlag, New York, 1989, and references contained therein.

[0065] Additionally, a manifold of routes allowing the attachment of chelating agents, crown ethers and cyclodextrins to other molecules is available to those of skill in the art. *See*, for example, Meares *et al.*, "Properties of In Vivo Chelate-Tagged Proteins and Polypeptides." In, MODIFICATION OF PROTEINS: FOOD, NUTRITIONAL, AND PHARMACOLOGICAL ASPECTS;" Feeney, *et al.*, Eds., American Chemical Society, Washington, D.C., 1982, pp. 370-387; Kasina *et al.*, *Bioconjugate Chem.*, **9**: 108-117 (1998); Song *et al.*, *Bioconjugate Chem.*, **8**: 249-255 (1997).

INTRODUCTION

[0066] The present invention provides polymeric species, and sugars, activated sugars, and nucleotide sugars that are conjugated to these polymers. The polymeric conjugates of the nucleotide sugars are generally substrates for an enzyme that transfers the sugar moiety and its polymeric substituent onto an appropriate acceptor moiety of a substrate. Accordingly, the invention also provides substrates modified by glycoconjugation using a polymeric conjugate of a nucleotide sugar and an appropriate enzyme. Substrates that can be glycoconjugated using a compound of the invention include peptides, e.g., glycopeptides, lipids, e.g., glycolipids and aglycones (sphingosines, ceramides).

[0067] As discussed in the preceding sections, art-recognized chemical methods of covalent PEGylation rely on chemical conjugation through reactive groups on amino acids or carbohydrates. Through careful design of the conjugate and the reaction conditions, useful conjugates have been prepared using chemically-mediated conjugation strategies. A major shortcoming of chemical conjugation of polymers to proteins or glycoproteins is the lack of selectivity of the activated polymers, which often results in attachment of polymers at sites implicated in protein or glycoprotein bioactivity. Several strategies have been developed to address site selective conjugation chemistries, however, only one universal method suitable for a variety of recombinant proteins has been developed.

[0068] In contrast to art-recognized methods, the present invention provides compounds that are of use in a novel strategy for highly selective, site-directed glycoconjugation of branched water-soluble polymers, e.g., glyco-PEGylation. In an exemplary embodiment of the invention, site directed attachment of branched water-soluble polymers is accomplished by *in*


vitro enzymatic glycosylation of specific peptide sequences using a nucleotide sugar or activated sugar of the invention. Glyco-conjugation can be performed enzymatically utilizing a glycosyltransferase, *e.g.*, a sialyltransferase, capable of transferring the species branched water-soluble polymer-sugar, *e.g.*, PEG-sialic acid, to a glycosylation site ("glyco-PEGylation").

[0069] As discussed above, the present invention provides a conjugate between a sugar having any desired carbohydrate structure, modified with a polymeric moiety. Sugar nucleotides and activated sugars based on these sugar structures are also a component of the invention. The polymeric modifying moiety is attached to the sugar moiety by enzymatic means, chemical means or a combination thereof, thereby producing a modified nucleotide sugar. The sugars are substituted with the polymeric modifying moiety at any desired position. In an exemplary embodiment, the sugar is a furanose that is substituted at one or more of C-1, C-2, C-3, C-4 or C-5. In another embodiment, the invention provides a pyranose that is substituted with the polymeric modifying moiety at one or more of C-1, C-2, C-3, C-4, C-5 or C-6. Preferably, the polymeric modifying moiety is attached directly to an oxygen, nitrogen or sulfur pendent from the carbon. Alternatively, the polymeric modifying moiety is attached to a linker that is interposed between the sugar and the modifying moiety. The linker is attached to an oxygen, nitrogen or sulfur pendent from the selected carbon.


[0070] In a presently preferred embodiment, the polymeric modifying moiety is appended to a position, that is selected such that the resulting conjugate functions as a substrate for an enzyme used to ligate the modified sugar moiety to another species, *e.g.*, peptide, glycopeptide, lipid, glycolipid, etc. Exemplary enzymes are discussed in greater detail herein and include glycosyl transferases (sialyl transferases, glucosyl transferases, galactosyl transferases, N-acetylglucosyl transferases, N-acetylgalactosyl transferases, mannosyl transferases, fucosyl transferases, etc.). Exemplary sugar nucleotide and activated sugar conjugates of the invention also include substrates for mutant glycosidases and mutant glycoceramidases that are modified to have synthetic, rather than hydrolytic activity.

[0071] In an exemplary embodiment, the conjugate of the invention includes a sugar, activated sugar or nucleotide sugar that is conjugated to one or more polymer, *e.g.* a branched polymer. Exemplary polymers include both water-soluble and water-insoluble species.

[0072] In an exemplary embodiment, the polymeric modifying group is directly or indirectly attached to a pyranose or a furanose. For example:



In Formulae I and II, R^1 is H, CH_2OR^7 , COOR^7 or OR^7 , in which R^7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl. R^2 is H, OH, NH or a moiety that includes a nucleotide. An exemplary R^2 species according to this embodiment has the formula:




in which X^1 represents O or NH and R^8 is a nucleoside.

[0073] [0074] The symbols R^3 , R^4 , R^5 , R^6 and $\text{R}^{6'}$ independently represent H, substituted or unsubstituted alkyl, OR^9 , NHC(O)R^{10} . The index d is 0 or 1. R^9 and R^{10} are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid. At least one of R^3 , R^4 , R^5 , R^6 , and $\text{R}^{6'}$ includes the polymeric modifying moiety, *e.g.*, PEG. In an exemplary embodiment, R^6 and $\text{R}^{6'}$, together with the carbon to which they are attached are components of the side chain of sialic acid. In still a further exemplary embodiment, this side chain is modified with the polymeric modifying moiety (or a linker-polymeric modifying moiety) at one or more of C-6, C-7 or C-9.

[0075] The symbols R^3 , R^4 , R^5 and R^6 independently represent H, OR^9 , NHC(O)R^{10} . R^9 and R^{10} are independently selected from H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl. At least one of R^3 , R^4 , R^5 , R^6 , or $\text{R}^{6'}$ include the polymeric modifying moiety.

[0076] In another exemplary embodiment, the sugar moiety is a sialic acid moiety that has been oxidized and conjugated to a polymeric modifying moiety, such as is described in commonly assigned U.S. Provisional Patent Application No. _____ (Attorney Docket No. 040853-01-5150), filed January 6, 2005.

[0077] In an exemplary embodiment, the polymeric modifying moiety is joined to the sugar core through a linker:



in which R^{11} is the polymeric moiety and L is selected from a bond and a linking group, and w is an integer from 1-6, preferably 1-3 and more preferably, 1-2.

[0078] When L is a bond it is formed between a reactive functional group on a precursor of R^{11} and a reactive functional group of complementary reactivity on a precursor of L. As set forth herein, the selection and preparation of precursors with appropriate reactive functional groups is within the ability of those skilled in the art. Moreover, combining the precursors proceed by chemistries that are well-understood in the art.


[0079] In an exemplary embodiment L is a linking group that is formed from an amino acid, an amino acid mimetic, or small peptide (e.g., 1-4 amino acid residues) providing a modified sugar in which the polymeric modifying moiety is attached through a substituted alkyl linker. The linker is formed through reaction of the amine moiety and carboxylic acid (or a reactive derivative, e.g., active ester, acid halide, etc.) of the amino acid with groups of complementary reactivity on the precursors to L and R^{11} . The elements of the conjugate can be conjugated in essentially any convenient order. For example the precursor to L can be in place on the saccharide core prior to conjugating the precursors of R^{11} and L. Alternatively, an R^{11} -L cassette, bearing a reactive functionality on L can be prepared and subsequently linked to the saccharide through a reactive functional group of complementary reactivity on this species.

[0080] In an exemplary embodiments, the polymeric modifying moiety is R^3 and/or R^6 . In another exemplary embodiment, R^3 and/or R^6 includes both the polymeric modifying moiety and a linker, L, joining the polymeric moiety to the remainder of the molecule. In another exemplary embodiment, the polymeric modifying moiety is R^3 . And, in a further exemplary embodiment, R^3 includes both the polymeric modifying moiety and a linker, L, joining the polymeric moiety to the remainder of the molecule. In yet another exemplary embodiment in which the sugar is a sialic acid, the polymeric modifying moiety is at R^5 or attached at a position of the sialic acid side chain, e.g., C-9.


Linear Polymer Conjugates

[0081] In an exemplary embodiment, the present invention provides a sugar or activated sugar conjugate or nucleotide sugar conjugate that is formed between a linear polymer, such as a water-soluble or water-insoluble polymer. In the conjugates of the invention, the polymer is attached to a sugar, activated sugar or sugar nucleotide. As discussed herein, the polymer is linked to the sugar moiety, either directly or through a linker.

[0082] An exemplary compound according to this embodiment has a structure according to Formulae I or II, in which at least one of R^1 , R^3 , R^4 , R^5 or R^6 has the formula:



[0083] Another example according to this embodiment has the formula:




in which s is an integer from 0 to 20 and R^{11} is a linear polymeric modifying moiety.

[0084] PEG moieties of any molecular weight, e.g., 2 Kda, 5 Kda, 10 Kda, 20 Kda, 30 Kda and 40 Kda are of use in the present invention.

Branched Polymer Conjugates

[0085] In an exemplary embodiment, the polymeric modifying moiety is a branched structure that includes two or more polymeric chains attached to central moiety, having the formula:



in which R^{11} and L are as discussed above and w' is an integer from 2 to 6, preferably from 2 to 4 and more preferably from 2 to 3.

[0086] An exemplary precursor of use to form the conjugates according to this embodiment of the invention has the formula:




[0087] The branched polymer species according to this formula are essentially pure

water-soluble polymers. $X^{3'}$ is a moiety that includes an ionizable, e.g., COOH , H_2PO_4 , HSO_3 , HPO_3 , etc.) or other reactive functional group, e.g., *infra*. C is carbon. X^5 is preferably a non-reactive group (e.g., H, unsubstituted alkyl, unsubstituted heteroalkyl), and can be a polymeric arm. R^{12} and R^{13} are independently selected polymeric arms, e.g., nonpeptidic, nonreactive polymeric arms. X^2 and X^4 are linkage fragments that are preferably essentially non-reactive under physiological conditions, which may be the same or different. Alternatively, these linkages can include one or more moiety that is designed to degrade under physiologically relevant conditions, e.g., esters, disulfides, etc. X^2 and X^4 join polymeric arms R^{12} and R^{13} to C. When $X^{3'}$ is reacted with a reactive functional group of complementary reactivity on a linker, sugar or linker-sugar cassette, $X^{3'}$ is converted to a component of linkage fragment X^3 .


[0088] Exemplary linkage fragments for X^2 and X^4 include S, SC(O)NH , HNC(O)S , SC(O)O , O, NH, NHC(O) , (O)CNH and NHC(O)O , and OC(O)NH , CH_2S , CH_2O , $\text{CH}_2\text{CH}_2\text{O}$, $\text{CH}_2\text{CH}_2\text{S}$, $(\text{CH}_2)_a\text{O}$, $(\text{CH}_2)_a\text{S}$ or $(\text{CH}_2)_a\text{Y}'\text{-PEG}$ or $(\text{CH}_2)_a\text{Y}'\text{-PEG}$ wherein Y' is S or O and a is an integer from 1 to 50.

[0089] In an exemplary embodiment, the precursor (III), or activated derivative thereof, is bound to the sugar, activated sugar or sugar nucleotide through a reaction between $X^{3'}$ and a group of complementary reactivity on the sugar moiety. Alternatively, $X^{3'}$ reacts with a reactive functional group on a precursor to linker, L. One or more of R^1 , R^3 , R^4 , R^5 or R^6 of Formulae I and II can include the branched polymeric modifying moiety.

[0090] In an exemplary embodiment, the moiety:




is the linker arm, L. In this embodiment, an exemplary linker is derived from a natural or unnatural amino acid, amino acid analogue or amino acid mimetic, or a small peptide formed from one or more such species. For example, certain branched polymers found in the compounds of the invention have the formula:



[0091] X^a is a linking moiety that is formed by the reaction of a reactive functional group on a precursor of the branched polymeric modifying moiety and the sugar moiety, or a precursor to a linker. For example, when X^3 is a carboxylic acid, it can be activated and bound directly to an amine group pendent from an amino-saccharide (e.g., GalNH_2 , GlcNH_2 , ManNH_2 , etc.), forming an X^a that is an amide. Additional exemplary reactive functional groups and activated precursors are described hereinbelow. The index c represents an integer from 1 to 10. The other symbols have the same identity as those discussed above.


[0092] In another exemplary embodiment, X^a is a linking moiety formed with another linker:



in which X^b is a linking moiety and is independently selected from those groups set forth for X^a , and L^1 is a bond, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.

[0093] Exemplary species for X^a and X^b include S, SC(O)NH , HNC(O)S , SC(O)O , O, NH, NHC(O) , $(\text{O})\text{CNH}$ and NHC(O)O , and OC(O)NH .



[0094] For example,



in which s is an integer from 0 to 20 and R^{11} is a linear polymeric modifying moiety.



[0095] In another exemplary embodiment, X^4 is a peptide bond to R^{13} , which is an amino acid, di-peptide or tri-peptide in which the alpha-amine moiety and/or side chain heteroatom is modified with a polymer.

[0096] In a further exemplary embodiment, R^6 includes the branched polymeric modifying group and the modified sugar or nucleotide sugar has a formula that is selected from:



in which the identity of the radicals represented by the various symbols is the same as that discussed hereinabove. L^a is a substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl moiety. In an exemplary embodiment, L^a is a moiety of the side chain of sialic acid that is functionalized with the polymeric modifying moiety as shown.

[0097] In yet another exemplary embodiment, the invention provides sugars and nucleotide sugars that have the formula:



The identity of the radicals represented by the various symbols is the same as that discussed hereinabove. As those of skill will appreciate, the linker arm in Formulae VI and VIII is equally applicable to other modified sugars set forth herein.

[0098] The embodiments of the invention set forth above are further exemplified by reference to species in which the polymer is a water-soluble polymer, particularly poly(ethylene glycol) ("PEG"), e.g., methoxy-poly(ethylene glycol) ("m-PEG"). Those of skill will appreciate that the focus in the sections that follow is for clarity of illustration and the various motifs set forth using PEG as an exemplary polymer are equally applicable to species in which a polymer other than PEG is utilized.

Water-Soluble Polymers

[0099] Many water-soluble polymers are known to those of skill in the art and are useful in practicing the present invention. The term water-soluble polymer encompasses species such as saccharides (e.g., dextran, amylose, hyaluronic acid, poly(sialic acid), heparans, heparins,

etc.); poly (amino acids), *e.g.*, poly(aspartic acid) and poly(glutamic acid); nucleic acids; synthetic polymers (*e.g.*, poly(acrylic acid), poly(ethers), *e.g.*, poly(ethylene glycol); peptides, proteins, and the like. A polymer typically comprises at least two polymeric units. In an exemplary embodiment the polymer is from 2-25 units. In another exemplary embodiment the polymer comprises 2-8 polymeric units. The present invention may be practiced with any water-soluble polymer with the sole limitation that the polymer must include a point at which the remainder of the conjugate can be attached.

[0100] Methods for activation of polymers can also be found in WO 94/17039, U.S. Pat. No. 5,324,844, WO 94/18247, WO 94/04193, U.S. Pat. No. 5,219,564, U.S. Pat. No. 5,122,614, WO 90/13540, U.S. Pat. No. 5,281,698, and more WO 93/15189, and for conjugation between activated polymers and peptides, *e.g.* Coagulation Factor VIII (WO 94/15625), hemoglobin (WO 94/09027), oxygen carrying molecule (U.S. Pat. No. 4,412,989), ribonuclease and superoxide dismutase (Veronese *et al.*, *App. Biochem. Biotech.* **11**: 141-45 (1985)).

[0101] Preferred water-soluble polymers are those in which a substantial proportion of the polymer molecules in a sample of the polymer are of approximately the same molecular weight; such polymers are "homodisperse."

[0102] The present invention is further illustrated by reference to a poly(ethylene glycol) conjugate. Several reviews and monographs on the functionalization and conjugation of PEG are available. *See*, for example, Harris, *Macromol. Chem. Phys.* **C25**: 325-373 (1985); Scouten, *Methods in Enzymology* **135**: 30-65 (1987); Wong *et al.*, *Enzyme Microb. Technol.* **14**: 866-874 (1992); Delgado *et al.*, *Critical Reviews in Therapeutic Drug Carrier Systems* **9**: 249-304 (1992); Zalipsky, *Biocorjugate Chem.* **6**: 150-165 (1995); and Bhadra, *et al.*, *Pharmazie*, **57**:5-29 (2002). Routes for preparing reactive PEG molecules and forming conjugates using the reactive molecules are known in the art. For example, U.S. Patent No. 5,672,662 discloses a water soluble and isolatable conjugate of an active ester of a polymer acid selected from linear or branched poly(alkylene oxides), poly(oxyethylated polyols), poly(olefinic alcohols), and poly(acrylomorpholine).

[0103] U.S. Patent No. 6,376,604 sets forth a method for preparing a water-soluble 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl of the polymer with di(1-benzotriazolyl)carbonate in an organic solvent. The active ester is used to form conjugates with a biologically active agent such as a protein or peptide.


[0104] WO 99/45964 describes a conjugate comprising a biologically active agent and an activated water soluble polymer comprising a polymer backbone having at least one terminus linked to the polymer backbone through a stable linkage, wherein at least one terminus comprises a branching moiety having proximal reactive groups linked to the branching moiety, in which the biologically active agent is linked to at least one of the proximal reactive groups. Other branched poly(ethylene glycols) are described in WO 96/21469, U.S. Patent No. 5,932,462 describes a conjugate formed with a branched PEG molecule that includes a branched terminus that includes reactive functional groups. The free reactive groups are available to react with a biologically active species, such as a protein or peptide, forming conjugates between the poly(ethylene glycol) and the biologically active species. U.S. Patent No. 5,446,090 describes a bifunctional PEG linker and its use in forming conjugates having a peptide at each of the PEG linker termini.

[0105] Conjugates that include degradable PEG linkages are described in WO 99/34833; and WO 99/14259, as well as in U.S. Patent No. 6,348,558. Such degradable linkages are applicable in the present invention.

[0106] The art-recognized methods of polymer activation set forth above are of use in the context of the present invention in the formation of the branched polymers set forth herein and also for the conjugation of these branched polymers to other species, *e.g.*, sugars, sugar nucleotides and the like.

[0107] Exemplary modifying groups are discussed below. The modifying groups can be selected for their ability to impart to a peptide one or more desirable property. Exemplary properties include, but are not limited to, enhanced pharmacokinetics, enhanced pharmacodynamics, improved biodistribution, providing a polyvalent species, improved water solubility, enhanced or diminished lipophilicity, and tissue targeting.


[0108] Exemplary poly(ethylene glycol) molecules of use in the invention include, but are not limited to, those having the formula:




in which A² is H, OH, NH₂, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl,


substituted or unsubstituted heteroalkyl, *e.g.*, acetal, OHC- , $\text{H}_2\text{N-(CH}_2)_q\text{-}$, $\text{HS-(CH}_2)_q\text{-}$ or $\text{-(CH}_2)_q\text{C(Y}^b\text{)Z}^b$. The index “e” represents an integer from 1 to 2500. The indices b, d, and q independently represent integers from 0 to 20. The symbols Z^a and Z^b independently represent OH, NH_2 , leaving groups, *e.g.*, imidazole, p-nitrophenyl, HOBT, tetrazole, halide, S-R^a , the alcohol portion of activated esters; $\text{-(CH}_2)_p\text{C(Y}^b\text{)V}$, or $\text{-(CH}_2)_p\text{U(CH}_2)_s\text{C(Y}^b\text{)}_v$. The symbol Y^a represents H(2) , $=\text{O}$, $=\text{S}$, $=\text{N-R}^b$. The symbols X^a , Y^a , Y^b , A^1 , and U independently represent the moieties O, S, N-R^c . The symbol V represents OH, NH_2 , halogen, S-R^a , the alcohol component of activated esters, the amine component of activated amides, sugar-nucleotides, and proteins. The indices p, q, s and v are members independently selected from the integers from 0 to 20. The symbols R^a , R^b , and R^c independently represent H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycloalkyl and substituted or unsubstituted heteroaryl.

[0109] Specific embodiments of linear and branched polymers, *e.g.*, PEGs, of use in the invention include:




and carbonates and active esters of these species, such as:





can be used to form the linear and branched polymeric species, linker arm conjugates of these species and conjugates between these compounds and sugars and nucleotide sugars. The indices *e* and *f* are independently selected from 1 to 2500.


[0110] Other exemplary activating, or leaving groups, appropriate for activating linear PEGs of use in preparing the compounds set forth herein include, but are not limited to the species:



It is well within the abilities of those of skill in the art to select an appropriate activating group for a selected moiety on the precursor to the polymeric modifying moiety.


[0111] PEG molecules that are activated with these and other species and methods of making the activated PEGs are set forth in WO 04/083259.

[0112] In exemplary embodiments, the branched polymer is a PEG based upon a cysteine, serine, lysine, di- or tri-lysine core. Thus, further exemplary branched PEGs include:



The indices e and f are independently selected from 1 to 2500.

[0113] In yet another embodiment, the branched PEG moiety is based upon a tri-lysine peptide. The tri-lysine can be mono-, di-, tri-, or tetra-PEG-ylated. Exemplary species according to this embodiment have the formulae:




in which e , f and f' are independently selected integers from 1 to 2500; and q , q' and q'' are independently selected integers from 0 to 20.

[0114] In exemplary embodiments of the invention, the PEG is m-PEG (5 kD, 10 kD, 20kD, 30 kD or 40kD). An exemplary branched PEG species is a lysine, serine- or cysteine-(m-PEG)₂ in which the m-PEG is a 20 kD m-PEG.

[0115] As will be apparent to those of skill, the branched polymers of use in the invention include variations on the themes set forth above. For example the di-lysine-PEG conjugate shown above can include three polymeric subunits, the third bonded to the α -amine shown as unmodified in the structure above. Similarly, the use of a tri-lysine functionalized with three or four polymeric subunits is within the scope of the invention.

[0116] Those of skill in the art will appreciate that one or more of the m-PEG arms of the branched polymer can be replaced by a PEG moiety with a different terminus, *e.g.*, OH, COOH, NH₂, C₂-C₁₀-alkyl, etc. Moreover, the structures above are readily modified by inserting alkyl linkers (or removing carbon atoms) between the α -carbon atom and the functional group of the side chain. Thus, "homo" derivatives and higher homologues, as well as lower homologues are within the scope of cores for branched PEGs of use in the present invention.

[0117] The branched PEG species set forth herein are readily prepared by methods such as that set forth in the scheme below:




in which X^b is O, NH or S and r is an integer from 1 to 10. The indices e and f are independently selected integers from 1 to 2500. Exemplary branched PEG species are 10,000, 15,000, 20,000, 30,000 and 40,000 daltons.

[0118] Thus, according to this scheme, a natural or unnatural amino acid is contacted with an activated m-PEG derivative, in this case the tosylate, forming **1** by alkylating the side-chain heteroatom X^b . The mono-functionalized m-PEG amino acid is submitted to N-acylation conditions with a reactive m-PEG derivative, thereby assembling branched m-PEG **2**. As one of skill will appreciate, the tosylate leaving group can be instead any suitable leaving group, *e.g.*, halogen, mesylate, triflate, etc. Similarly, the reactive carbonate utilized to acylate the amine can be instead an active ester, *e.g.*, N-hydroxysuccinimide, etc., or the acid can be activated *in situ* using a dehydrating agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, etc.


[0119] In the exemplary scheme set forth above, the modifying group is a linear PEG moiety, however, any modifying group, *e.g.*, water-soluble polymer, water-insoluble polymer, branched polymer, therapeutic moiety, etc., can be incorporated in a glycosyl moiety through

[0120] Further branched polymeric species of use in the compounds of the invention are exemplified by branched cores functionalized with PEG, such as the examples set forth below:



in which R^{14} is OH or another reactive functional group. An exemplary reactive functional group is $C(O)Q'$, in which Q' is selected such that $C(O)Q'$ is a reactive functional group. Exemplary species for Q' include halogen, NHS, pentafluorophenyl, HOBT, HOAt, and p-nitrophenyl. The index "e" and the index "f" are integers independently selected from 1 to 2500.

[0121] The branched compounds set forth above, and additional branched compounds of use in the compounds of the invention are readily prepared from such starting materials as:



Polymer Modified Sugar Species

[0122] The sugar moiety of the nucleotide sugars of the invention can be selected from both natural and unnatural furanoses and hexanoses. The unnatural saccharides optionally include an alkylated or acylated hydroxyl and/or amine moiety, e.g., ethers, esters and amide substituents on the ring. Other unnatural saccharides include an H, hydroxyl, ether, ester or amide substituent at a position on the ring at which such a substituent is not present in the natural saccharide. The sugar moiety can be a mono-, oligo- or poly-saccharide.

[0123] Exemplary natural sugars of use in the present invention include glucose, galactose, fucose, mannose, xylanose, ribose, N-acetyl glucose, sialic acid and N-acetyl galactose.

[0124] Similarly, the nucleoside can be selected from both natural and unnatural or unusual nucleosides. Exemplary natural nucleosides of use in the present invention include cytosine, thymine, guanine, adenine and uracil. Unusual nucleosides may include but are not limited to such molecules as spongouridin and spongothymidin. The art is replete with structures of unnatural and unusual nucleosides and methods of making them.

[0125] Exemplary modified sugar nucleotides of the invention include GDP-Man, GDP-Fuc, UDP-Gal, UDP-Gal-NH₂, UDP-GalNAc, UDP-Glc, UDP-Glc-NH₂, UDP-GlcNAc, UDP-Glc, UDP-GlcUA and CMP-Sia. As with the sugars of the invention discussed above, the sugar nucleotides of the invention can be substituted with a polymeric modifying moiety (or linker-modifying moiety) at any position of the saccharide. For example, compounds encompassed by the invention include those in which the L-R¹¹ moiety is conjugated to C-5 of a furanose-based nucleotide sugar or C-6 of a pyranose-based nucleotide sugar.

[0126] Exemplary moieties attached to the conjugates disclosed herein include, but are not limited to, PEG derivatives (e.g., alkyl-PEG, acyl-PEG, acyl-alkyl-PEG, alkyl-acyl-PEG carbamoyl-PEG, aryl-PEG), PPG derivatives (e.g., alkyl-PPG, acyl-PPG, acyl-alkyl-PPG, alkyl-acyl-PPG carbamoyl-PPG, aryl-PPG), therapeutic moieties, diagnostic moieties, mannose-6-phosphate, heparin, heparan, SLe_x, mannose, mannose-6-phosphate, Sialyl Lewis X, FGF, VFGF, proteins, chondroitin, keratan, dermatan, albumin, integrins, antennary

oligosaccharides, peptides and the like. Methods of conjugating the various modifying groups to a saccharide moiety are readily accessible to those of skill in the art (POLY (ETHYLENE GLYCOL) CHEMISTRY : BIOTECHNICAL AND BIOMEDICAL APPLICATIONS, J. Milton Harris, Ed., Plenum Pub. Corp., 1992; POLY (ETHYLENE GLYCOL) CHEMICAL AND BIOLOGICAL APPLICATIONS, J. Milton Harris, Ed., ACS Symposium Series No. 680, American Chemical Society, 1997; Hermanson, BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and Dunn *et al.*, Eds. POLYMERIC DRUGS AND DRUG DELIVERY SYSTEMS, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991).

[0127] Exemplary sugar nucleotides that of the present invention, in their modified form, include nucleotide mono-, di- or triphosphates or analogs thereof of a UDP-glycoside, CMP-glycoside, or a GDP-glycoside. Even more preferably, the modified sugar nucleotide is selected from an UDP-galactose, UDP-galactosamine, UDP-glucose, UDP-glucosamine, GDP-mannose, GDP-fucose, CMP-sialic acid, or CMP-NeuAc. N-acetylamine derivatives of the sugar nucleotides are also of use in the method of the invention.

[0128] In other embodiments, the modified sugar is an activated sugar. Activated modified sugars, which are useful in the present invention are typically glycosides which have been synthetically altered to include an activated leaving group. As used herein, the term "activated leaving group" refers to those moieties, which are easily displaced in enzyme-regulated nucleophilic substitution reactions. Many activated sugars are known in the art. See, for example, Vocadlo *et al.*, In CARBOHYDRATE CHEMISTRY AND BIOLOGY, Vol. 2, Ernst *et al.* Ed., Wiley-VCH Verlag: Weinheim, Germany, 2000; Kodama *et al.*, *Tetrahedron Lett.* **34**: 6419 (1993); Loughheed, *et al.*, *J. Biol. Chem.* **274**: 37717 (1999)).

[0129] Examples of activating groups (leaving groups) include fluoro, chloro, bromo, tosylate ester, mesylate ester, triflate ester and the like. Preferred activated leaving groups, for use in the present invention, are those that do not significantly sterically encumber the enzymatic transfer of the glycoside to the acceptor. Accordingly, preferred embodiments of activated glycoside derivatives include glycosyl fluorides and glycosyl mesylates, with glycosyl fluorides being particularly preferred. Among the glycosyl fluorides, α -galactosyl fluoride, α -mannosyl fluoride, α -glucosyl fluoride, α -fucosyl fluoride, α -xylosyl fluoride, α -sialyl fluoride, α -N-acetylglucosaminyl fluoride, α -N-acetylgalactosaminyl fluoride, β -galactosyl fluoride, β -mannosyl fluoride, β -glucosyl fluoride, β -fucosyl fluoride, β -xylosyl

fluoride, β -sialyl fluoride, β -N-acetylglucosaminyl fluoride and β -N-acetylgalactosaminyl fluoride are most preferred.

[0130] By way of illustration, glycosyl fluorides can be prepared from the free sugar by first acetylating the sugar and then treating it with HF/pyridine. This generates the thermodynamically most stable anomer of the protected (acetylated) glycosyl fluoride (*i.e.*, the α -glycosyl fluoride). If the less stable anomer (*i.e.*, the β -glycosyl fluoride) is desired, it can be prepared by converting the peracetylated sugar with HBr/HOAc or with HCl to generate the anomeric bromide or chloride. This intermediate is reacted with a fluoride salt such as silver fluoride to generate the glycosyl fluoride. Acetylated glycosyl fluorides may be deprotected by reaction with mild (catalytic) base in methanol (*e.g.* NaOMe/MeOH). In addition, many glycosyl fluorides are commercially available.

[0131] Other activated glycosyl derivatives can be prepared using conventional methods known to those of skill in the art. For example, glycosyl mesylates can be prepared by treatment of the fully benzylated hemiacetal form of the sugar with mesyl chloride, followed by catalytic hydrogenation to remove the benzyl groups.

[0132] In a further exemplary embodiment, the modified sugar is an oligosaccharide having an antennary structure. In another embodiment, one or more of the termini of the antennae bear the modifying moiety. When more than one modifying moiety is attached to an oligosaccharide having an antennary structure, the oligosaccharide is useful to “amplify” the modifying moiety; each oligosaccharide unit conjugated to the peptide attaches multiple copies of the modifying group to the peptide. The general structure of a typical conjugate of the invention as set forth in the drawing above, encompasses multivalent species resulting from preparing a conjugate of the invention utilizing an antennary structure. Many antennary saccharide structures are known in the art, and the present method can be practiced with them without limitation.

[0133] In an exemplary embodiment, the activated, modified sugar is a substrate for a mutant enzyme that transfers the sugar onto an appropriate acceptor moiety of a substrate. Exemplary mutant enzymes include, *e.g.*, those set forth in commonly assigned PCT publications WO03/046150 and WO03/045980

[0134] Water-soluble polymer modified sugar, activated sugar and nucleotide sugar species in which the sugar moiety is modified with a water-soluble polymer, *e.g.*, a water-soluble


polymer, are of use in the present invention. An exemplary modified sugar nucleotide bears a sugar group that is modified through an amine moiety on the sugar. Modified sugar nucleotides, e.g., saccharyl-amine derivatives of a sugar nucleotide, are also of use in the methods of the invention. For example, a saccharyl amine (without the modifying group) can be enzymatically conjugated to a peptide (or other species) and the free saccharyl amine moiety subsequently conjugated to a desired modifying group. Alternatively, the modified sugar nucleotide can function as a substrate for an enzyme that transfers the modified sugar to a saccharyl acceptor on a substrate, e.g., a peptide, glycopeptide, lipid, aglycone, glycolipid, etc.

[0135] In one embodiment, the sugar is conjugated to a branched polymeric species, such as those set forth herein.

[0136] In another embodiment, the sugar moiety is a modified sialic acid. When sialic acid is the sugar, the sialic acid is substituted with the modifying group at either the 9-position on the pyruvyl side chain or at the 5-position on the amine moiety that is normally acetylated in sialic acid.


[0137] In another embodiment, in which the saccharide core is galactose or glucose, R^5 is $NHC(O)Y$.

[0138] In an exemplary embodiment, the modified sugar is based upon a 6-amino-N-acetyl-glycosyl moiety. As shown below for N-acetylgalactosamine, the 6-amino-sugar moiety is readily prepared by standard methods:



[0162] In the scheme above, the index n represents an integer from 1 to 2500, preferably from 10 to 1500, and more preferably from 10 to 1200. The symbol “A” represents an activating group, *e.g.*, a halo, a component of an activated ester (*e.g.*, a *N*-hydroxysuccinimide ester), a component of a carbonate (*e.g.*, *p*-nitrophenyl carbonate) and the like. Those of skill in the art will appreciate that other PEG-amide nucleotide sugars are readily prepared by this and analogous methods. Moreover, a branched polymer, as set forth herein, can be substituted for the linear PEG.

[0139] Another exemplary polymerically modified nucleotide sugar of the invention in which the C-6 position is modified has the formula:



in which X^6 is a bond or O, J is S or O, and y is 0 or 1. The indices e and f are independently selected from 1 to 2500.

[0140] In other exemplary embodiments, the amide moiety is replaced by a group such as a urethane or a urea.


[0141] In the discussion that follows, a number of specific examples of modified sugars that are useful in practicing the present invention are set forth. In the exemplary embodiments, a sialic acid derivative is utilized as the sugar nucleus to which the modifying group is attached. The focus of the discussion on sialic acid derivatives is for clarity of illustration only and should not be construed to limit the scope of the invention. Those of skill in the art will appreciate that a variety of other sugar moieties can be activated and derivatized in a manner analogous to that set forth using sialic acid as an example. For example, numerous methods are available for modifying galactose, glucose, N-acetylgalactosamine and fucose to name a few sugar substrates, which are readily modified by art recognized methods. *See*, for example, Elhalabi *et al.*, *Curr. Med. Chem.* 6: 93 (1999); and Schafer *et al.*, *J. Org. Chem.* 65: 24 (2000)).

[0142] In FIG. 2, a general scheme according to the present invention is set forth. Thus, according to FIG. 2, an amide conjugate between mannosamine and a protected amino acid is formed by contacting mannosamine with an N-protected amino acid under conditions appropriate to form the conjugate. The carboxyl terminus of the protected amino acid is activated *in situ* or it is optionally converted to a reactive group that is stable to storage, e.g., N-hydroxy-succinimide. The amino acid can be selected from any natural or non-natural amino acid. Those of skill in the art understand how to protect side-chain amino acids from undesirably reacting in the method of the invention. The amide conjugate is reacted with pyruvate and sialic acid aldolase under conditions appropriate to convert the amide conjugate to a sialic acid amide conjugate, which is subsequently converted to a nucleotide phosphate sialic acid amide conjugate by reaction of the sialic acid amide conjugate with a precursor of the nucleotide phosphate and an appropriate enzyme. In an exemplary embodiment, the precursor is cytidine triphosphate and the enzyme is a synthetase. Following the formation of the nucleotide sugar, the amino acid amine is deprotected, providing a free, reactive amine amine. The amine serves as a locus for conjugating the modifying moiety to the nucleotide sugar. In FIG. 2, the modifying moiety is exemplified by a water-soluble polymer, i.e., poly(ethylene glycol), e.g., PEG, m-PEG, etc.

[0143] The present invention is further exemplified in FIG. 3, which sets forth a scheme for preparing sialic acid-glycyl-PEG-cytidine monophosphate. Similar to the scheme set forth in


FIG. 2, that of **FIG. 3** originates with mannosamine. The sugar is conjugated with FMOC-glycine, using the N-hydroxysuccinimide activated derivative of the protected amino acid. The resulting amide conjugate is converted to the corresponding sialic acid by the action of sialic acid aldolase on the conjugate and pyruvate. The resulting sialic acid conjugate is converted to the cytidine monophosphate analogue using cytidine triphosphate and a synthetase. The CMP-analogue is deprotected by removing the protecting group from the amino acid amine moiety, converting this moiety to a reactive locus for conjugation. The amine moiety is reacted with an activated PEG species (m-PEG-O-nitrophenyl carbonate), thereby forming the sialic acid-glycyl-PEG-cytidine monophosphate.

[0144] Exemplary sugar cores based upon sialic acid have the formula:




in which D is -OH or $(R^{11})_w-L-$. The symbol G represents H, $(R^{11})_w-L-$ or $-C(O)(C_1-C_6)alkyl$. R^{11} is as is as described above. At least one of D and G is $R^{11}-L-$.

[0145] In another embodiment, the invention provides a sugar, activated sugar or sugar nucleotide that comprises the structure:




in which L^2 is as described above in the context of L, e.g., a bond, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl group. The index e represents an integer from 1 to about 2500.

[0146] In another embodiment, the sugar or sugar nucleotide comprises the structure:




in which s is selected from the integers from 0 to 20, and e is 1 to 2500.

[0147] Selected sialic acid-based nucleotide sugars functionalized with a branched polymer have the formula:





in which AA is an amino acid residue, PEG is poly(ethylene glycol) or methoxy-poly(ethylene glycol) and NP is a nucleotide, which is linked to the glycosyl moiety via a phosphodiester bond ("nucleotide phosphate"). Those of skill will appreciate that ONP can be replaced by an activating moiety as discussed herein.

[0148] In still further embodiments, the sialic acid derivative has a structure that is a member selected from:




in which X^6 is a bond or O, and J is S or O. The indices a, b and c are independently selected from 0 to 20, and e and f are independently selected from 1 to 2500.

[0149] Moreover, as discussed above, the present invention provides nucleotide sugars that are modified with a water-soluble polymer, which is either straight-chain or branched. For example, compounds having the formula shown below are within the scope of the present invention:




in which X^6 is O or a bond, and J is S or O. The indices e and f are independently selected from 1 to 2500.

[0150] Also provided are conjugates of peptides and glycopeptides, lipids and glycolipids that include the compositions of the invention. The conjugates are formed by combining a nucleotide sugar or activated sugar of the invention and a substrate with an appropriate acceptor moiety for the sugar moiety and an enzyme for which the modified nucleotide sugar is a substrate under conditions appropriate to transfer the modified sugar from the nucleotide sugar onto the acceptor moiety. For example, the invention provides conjugates having the following formulae:



wherein J and X⁶ are as discussed above. The indices a, b, c, e and f are as discussed above.

[0151] Selected compounds of the invention are based on species having the stereochemistry of mannose, galactose and glucose. The general formulae of these compounds are:




in which one of R³-R⁶ is the modifying moiety, e.g., polymeric modifying moiety or the polymeric modifying moiety-linker construct.

[0152] As discussed above, certain compounds of the present invention are polymeric modified sugar nucleotides. Exemplary sugar nucleotides that are used in the present invention in their modified form include nucleotide mono-, di- or triphosphates or analogs thereof. In a preferred embodiment, the modified sugar nucleotide is selected from a UDP-glycoside, CMP-glycoside, or a GDP-glycoside. Even more preferably, the modified sugar

nucleotide is selected from an UDP-galactose, UDP-galactosamine, UDP-glucose, UDP-glucosamine, GDP-mannose, GDP-fucose, CMP-sialic acid, or CMP-Sia. In an exemplary embodiment, the nucleotide mono- di- or tri-phosphate is attached to C-1.


[0153] The saccharyl-amine derivatives of the sugar nucleotides are also of use in the method of the invention. For example, the saccharyl amine (without the modifying group) can be enzymatically conjugated to a peptide (or other species) and the free saccharyl amine moiety subsequently conjugated to a desired modifying group.

[0154] The sugar nucleotide conjugates of the invention are described generically by the formula:




in which the symbols represent groups as discussed above. When the sugar core is mannose, the polymeric modifying moiety is preferably at R³, R⁴ or R⁶. For glucose, the polymeric modifying moiety is optionally at R⁵ or R⁶. The index "u" is 0, 1 or 2.


[0155] A further exemplary nucleotide sugar of the invention, based on GDP mannose has the structure:



[0156] In a still further exemplary embodiment, the invention provides a conjugate, based on UDP galactose having the structure:



[0157] In another exemplary embodiment, the nucleotide sugar is based on glucose and has the formula:



In each of the three preceding formulae, the identity of the radicals and indices is as discussed above.

[0158] As is apparent to those of skill in the art, the linear PEG moiety can be replaced by a branched polymeric or other linear polymeric species as described herein.

[0159] In one embodiment in which the saccharide core is galactose or glucose, R⁵ is NHC(O)Y.

Water-insoluble polymers

[0160] In another embodiment, analogous to those discussed above, the modified sugars include a water-insoluble polymer, rather than a water-soluble polymer. A water-insoluble polymer, like a water soluble polymer is typically comprised of at least two polymeric units. In one exemplary embodiment the polymer is comprised of from 2 to 25 polymeric units. In another exemplary embodiment the polymer is comprised of 2 to 8 polymeric units. The conjugates of the invention may also include one or more water-insoluble polymers. This embodiment of the invention is illustrated by the use of the conjugate as a vehicle with which to deliver a therapeutic peptide in a controlled manner. Polymeric drug delivery systems are known in the art. *See, for example, Dunn et al., Eds. POLYMERIC DRUGS AND DRUG*

DELIVERY SYSTEMS, ACS Symposium Series Vol. 469, American Chemical Society, Washington, D.C. 1991. Those of skill in the art will appreciate that substantially any known drug delivery system is applicable to the conjugates of the present invention.

[0161] Representative water-insoluble polymers include, but are not limited to, polyphosphazines, poly(vinyl alcohols), polyamides, polycarbonates, polyalkylenes, polyacrylamides, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly(vinyl acetate), polyvinyl chloride, polystyrene, polyvinyl pyrrolidone, pluronics and polyvinylphenol and copolymers thereof.

[0162] Synthetically modified natural polymers of use in conjugates of the invention include, but are not limited to, alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, and nitrocelluloses. Particularly preferred members of the broad classes of synthetically modified natural polymers include, but are not limited to, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxymethyl cellulose, cellulose triacetate, cellulose sulfate sodium salt, and polymers of acrylic and methacrylic esters and alginic acid.

[0163] These and the other polymers discussed herein can be readily obtained from commercial sources such as Sigma Chemical Co. (St. Louis, MO.), Polysciences (Warrenton, PA.), Aldrich (Milwaukee, WI.), Fluka (Ronkonkoma, NY), and BioRad (Richmond, CA), or else synthesized from monomers obtained from these suppliers using standard techniques.

[0164] Representative biodegradable polymers of use in the conjugates of the invention include, but are not limited to, polylactides, polyglycolides and copolymers thereof, poly(ethylene terephthalate), poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), polyanhydrides, polyorthoesters, blends and copolymers thereof. Of particular use are compositions that form gels, such as those including collagen, pluronics and the like.

[0165] The polymers of use in the invention include "hybrid" polymers that include water-insoluble materials having within at least a portion of their structure, a bioresorbable molecule. An example of such a polymer is one that includes a water-insoluble copolymer, which has a bioresorbable region, a hydrophilic region and a plurality of crosslinkable functional groups per polymer chain.

[0166] For purposes of the present invention, "water-insoluble materials" includes materials that are substantially insoluble in water or water-containing environments. Thus, although certain regions or segments of the copolymer may be hydrophilic or even water-soluble, the polymer molecule, as a whole, does not to any substantial measure dissolve in water.

[0167] For purposes of the present invention, the term "bioresorbable molecule" includes a region that is capable of being metabolized or broken down and resorbed and/or eliminated through normal excretory routes by the body. Such metabolites or break down products are preferably substantially non-toxic to the body.

[0168] The bioresorbable region may be either hydrophobic or hydrophilic, so long as the copolymer composition as a whole is not rendered water-soluble. Thus, the bioresorbable region is selected based on the preference that the polymer, as a whole, remains water-insoluble. Accordingly, the relative properties, *i.e.*, the kinds of functional groups contained by, and the relative proportions of the bioresorbable region, and the hydrophilic region are selected to ensure that useful bioresorbable compositions remain water-insoluble.

[0169] Exemplary resorbable polymers include, for example, synthetically produced resorbable block copolymers of poly(α -hydroxy-carboxylic acid)/poly(oxyalkylene), (*see*, Cohn *et al.*, U.S. Patent No. 4,826,945). These copolymers are not crosslinked and are water-soluble so that the body can excrete the degraded block copolymer compositions. *See*, Younes *et al.*, *J Biomed. Mater. Res.* **21**: 1301-1316 (1987); and Cohn *et al.*, *J Biomed. Mater. Res.* **22**: 993-1009 (1988).

[0170] Presently preferred bioresorbable polymers include one or more components selected from poly(esters), poly(hydroxy acids), poly(lactones), poly(amides), poly(ester-amides), poly(amino acids), poly(anhydrides), poly(orthoesters), poly(carbonates), poly(phosphazines), poly(phosphoesters), poly(thioesters), polysaccharides and mixtures thereof. More preferably still, the bioresorbable polymer includes a poly(hydroxy) acid

component. Of the poly(hydroxy) acids, polylactic acid, polyglycolic acid, polycaproic acid, polybutyric acid, polyvaleric acid and copolymers and mixtures thereof are preferred.

[0171] In addition to forming fragments that are absorbed *in vivo* ("bioresorbed"), preferred polymeric coatings for use in the methods of the invention can also form an excretable and/or metabolizable fragment.

[0172] Higher order copolymers can also be used in the present invention. For example, Casey *et al.*, U.S. Patent No. 4,438,253, which issued on March 20, 1984, discloses tri-block copolymers produced from the transesterification of poly(glycolic acid) and an hydroxyl-ended poly(alkylene glycol). Such compositions are disclosed for use as resorbable monofilament sutures. The flexibility of such compositions is controlled by the incorporation of an aromatic orthocarbonate, such as tetra-p-tolyl orthocarbonate into the copolymer structure.

[0173] Other polymers based on lactic and/or glycolic acids can also be utilized. For example, Spinu, U.S. Patent No. 5,202,413, which issued on April 13, 1993, discloses biodegradable multi-block copolymers having sequentially ordered blocks of polylactide and/or polyglycolide produced by ring-opening polymerization of lactide and/or glycolide onto either an oligomeric diol or a diamine residue followed by chain extension with a di-functional compound, such as, a diisocyanate, diacylchloride or dichlorosilane.

[0174] Bioresorbable regions of coatings useful in the present invention can be designed to be hydrolytically and/or enzymatically cleavable. For purposes of the present invention, "hydrolytically cleavable" refers to the susceptibility of the copolymer, especially the bioresorbable region, to hydrolysis in water or a water-containing environment. Similarly, "enzymatically cleavable" as used herein refers to the susceptibility of the copolymer, especially the bioresorbable region, to cleavage by endogenous or exogenous enzymes.

[0175] When placed within the body, the hydrophilic region can be processed into excretable and/or metabolizable fragments. Thus, the hydrophilic region can include, for example, polyethers, polyalkylene oxides, polyols, poly(vinyl pyrrolidone), poly(vinyl alcohol), poly(alkyl oxazolines), polysaccharides, carbohydrates, peptides, proteins and copolymers and mixtures thereof. Furthermore, the hydrophilic region can also be, for example, a poly(alkylene) oxide. Such poly(alkylene) oxides can include, for example, poly(ethylene) oxide, poly(propylene) oxide and mixtures and copolymers thereof.

[0176] Polymers that are components of hydrogels are also useful in the present invention. Hydrogels are polymeric materials that are capable of absorbing relatively large quantities of water. Examples of hydrogel forming compounds include, but are not limited to, polyacrylic acids, sodium carboxymethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidine, gelatin, carrageenan and other polysaccharides, hydroxyethylenemethacrylic acid (HEMA), as well as derivatives thereof, and the like. Hydrogels can be produced that are stable, biodegradable and bioresorbable. Moreover, hydrogel compositions can include subunits that exhibit one or more of these properties.

[0177] Bio-compatible hydrogel compositions whose integrity can be controlled through crosslinking are known and are presently preferred for use in the methods of the invention. For example, Hubbell *et al.*, U.S. Patent Nos. 5,410,016, which issued on April 25, 1995 and 5,529,914, which issued on June 25, 1996, disclose water-soluble systems, which are crosslinked block copolymers having a water-soluble central block segment sandwiched between two hydrolytically labile extensions. Such copolymers are further end-capped with photopolymerizable acrylate functionalities. When crosslinked, these systems become hydrogels. The water soluble central block of such copolymers can include poly(ethylene glycol); whereas, the hydrolytically labile extensions can be a poly(α -hydroxy acid), such as polyglycolic acid or polylactic acid. See, Sawhney *et al.*, *Macromolecules* **26**: 581-587 (1993).

[0178] In another embodiment, the gel is a thermoreversible gel. Thermoreversible gels including components, such as pluronics, collagen, gelatin, hyaluronic acid, polysaccharides, polyurethane hydrogel, polyurethane-urea hydrogel and combinations thereof are presently preferred.

[0179] In yet another exemplary embodiment, the conjugate of the invention includes a component of a liposome. Liposomes can be prepared according to methods known to those skilled in the art, for example, as described in Eppstein *et al.*, U.S. Patent No. 4,522,811, which issued on June 11, 1985. For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearyl phosphatidyl ethanolamine, stearyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its pharmaceutically acceptable salt is then introduced into the container. The container is then swirled by hand to free lipid

material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

[0180] The above-recited microparticles and methods of preparing the microparticles are offered by way of example and they are not intended to define the scope of microparticles of use in the present invention. It will be apparent to those of skill in the art that an array of microparticles, fabricated by different methods, is of use in the present invention.

[0181] The structural formats discussed above in the context of the water-soluble polymers, both straight-chain and branched are generally applicable with respect to the water-insoluble polymers as well. Thus, for example, the cysteine, serine, dilysine, and trilysine branching cores can be functionalized with two water-insoluble polymer moieties. The methods used to produce these species are generally closely analogous to those used to produce the water-soluble polymers.

[0182] The *in vivo* half-life of therapeutic glycopeptides can also be enhanced with PEG moieties such as polyethylene glycol (PEG). For example, chemical modification of proteins with PEG (PEGylation) increases their molecular size and decreases their surface- and functional group-accessibility, each of which are dependent on the size of the PEG attached to the protein. This results in an improvement of plasma half-lives and in proteolytic-stability, and a decrease in immunogenicity and hepatic uptake (Chaffee *et al. J. Clin. Invest.* **89**: 1643-1651 (1992); Pyatak *et al. Res. Commun. Chem. Pathol Pharmacol.* **29**: 113-127 (1980)). PEGylation of interleukin-2 has been reported to increase its antitumor potency *in vivo* (Katre *et al. Proc. Natl. Acad. Sci. USA.* **84**: 1487-1491 (1987)) and PEGylation of a F(ab')₂ derived from the monoclonal antibody A7 has improved its tumor localization (Kitamura *et al. Biochem. Biophys. Res. Commun.* **28**: 1387-1394 (1990)). Thus, in another embodiment, the *in vivo* half-life of a peptide derivatized with a PEG moiety by a method of the invention is increased relevant to the *in vivo* half-life of the non-derivatized peptide.

[0183] The increase in peptide *in vivo* half-life is best expressed as a range of percent increase in this quantity. The lower end of the range of percent increase is about 40%, about 60%, about 80%, about 100%, about 150% or about 200%. The upper end of the range is about 60%, about 80%, about 100%, about 150%, or more than about 250%.

Preparation of Modified Sugars

[0184] In general, the sugar moiety and the modifying group are linked together through the use of reactive groups, which are typically transformed by the linking process into a new organic functional group or unreactive species. The sugar reactive functional group(s), is located at any position on the sugar moiety. Reactive groups and classes of reactions useful in practicing the present invention are generally those that are well known in the art of bioconjugate chemistry. Currently favored classes of reactions available with reactive sugar moieties are those, which proceed under relatively mild conditions. These include, but are not limited to nucleophilic substitutions (*e.g.*, reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (*e.g.*, enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (*e.g.*, Michael reaction, Diels-Alder addition). These and other useful reactions are discussed in, for example, March, *ADVANCED ORGANIC CHEMISTRY*, 3rd Ed., John Wiley & Sons, New York, 1985; Hermanson, *BIOCONJUGATE TECHNIQUES*, Academic Press, San Diego, 1996; and Feeney *et al.*, *MODIFICATION OF PROTEINS*; *Advances in Chemistry Series*, Vol. 198, American Chemical Society, Washington, D.C., 1982.

[0185] Useful reactive functional groups pendent from a sugar nucleus, linker precursor or polymeric modifying moiety precursor include, but are not limited to:

- (a) carboxyl groups and various derivatives thereof including, but not limited to, N-hydroxysuccinimide esters, N-hydroxybenztriazole esters, acid halides, acyl imidazoles, thioesters, p-nitrophenyl esters, alkyl, alkenyl, alkynyl and aromatic esters;
- (b) hydroxyl groups, which can be converted to, *e.g.*, esters, ethers, aldehydes, *etc.*
- (c) haloalkyl groups, wherein the halide can be later displaced with a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion, thereby resulting in the covalent attachment of a new group at the functional group of the halogen atom;
- (d) dienophile groups, which are capable of participating in Diels-Alder reactions such as, for example, maleimido groups;
- (e) aldehyde or ketone groups, such that subsequent derivatization is possible via formation of carbonyl derivatives such as, for example, imines, hydrazones,


semicarbazones or oximes, or via such mechanisms as Grignard addition or alkyllithium addition;

- (f) sulfonyl halide groups for subsequent reaction with amines, for example, to form sulfonamides;
- (g) thiol groups, which can be, for example, converted to disulfides or reacted with acyl halides;
- (h) amine or sulfhydryl groups, which can be, for example, acylated, alkylated or oxidized;
- (i) alkenes, which can undergo, for example, cycloadditions, acylation, Michael addition, *etc.*; and
- (j) epoxides, which can react with, for example, amines and hydroxyl compounds.

[0186] The reactive functional groups can be chosen such that they do not participate in, or interfere with, the reactions necessary to assemble the reactive sugar nucleus or modifying group. Alternatively, a reactive functional group can be protected from participating in the reaction by the presence of a protecting group. Those of skill in the art understand how to protect a particular functional group such that it does not interfere with a chosen set of reaction conditions. For examples of useful protecting groups, *see*, for example, Greene *et al.*, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, New York, 1991.

[0187] In the discussion that follows, a number of specific examples of modified sugars that are useful in practicing the present invention are set forth. In the exemplary embodiments, a sialic acid derivative is utilized as the sugar nucleus to which the modifying group is attached. The focus of the discussion on sialic acid derivatives is for clarity of illustration only and should not be construed to limit the scope of the invention. Those of skill in the art will appreciate that a variety of other sugar moieties can be activated and derivatized in a manner analogous to that set forth using sialic acid as an example. For example, numerous methods are available for modifying galactose, glucose, N-acetylgalactosamine and fucose to name a few sugar substrates, which are readily modified by art recognized methods. *See*, for example, Elhalabi *et al.*, *Curr. Med. Chem.* 6: 93 (1999); and Schafer *et al.*, *J. Org. Chem.* 65: 24 (2000)).


[0188] In Scheme 1 below, the amino glycoside **1**, is treated with the active ester of a protected amino acid (*e.g.*, glycine) derivative, converting the sugar amine residue into the corresponding protected amino acid amide adduct. The adduct is treated with an aldolase to form α -hydroxy carboxylate **2**. Compound **2** is converted to the corresponding CMP derivative by the action of CMP-SA synthetase, followed by catalytic hydrogenation of the CMP derivative to produce compound **3**. The amine introduced via formation of the glycine adduct is utilized as a locus of PEG or PPG attachment by reacting compound **3** with an activated (*m*-) PEG or (*m*-) PPG derivative (*e.g.*, PEG-C(O)NHS, PPG-C(O)NHS), producing **4** or **5**, respectively.




Scheme 1

As those of skill will appreciate, the polymeric modifying moiety can also be a branched moiety, such as those described herein.

[0189] An exemplary scheme for preparing the branched polymerically-modified sugars of the invention is provided below:




[0190] Another exemplary scheme for preparing the polymerically-modified sugars of the invention is set forth below:



[0191] Table 1 sets forth representative examples of sugar monophosphates that are derivatized with a polymeric modifying moiety, e.g., a branched- or straight-chain PEG or


PPG moiety. Certain of the compounds of Table 1 are prepared by the method of Scheme 1. Other derivatives are prepared by art-recognized methods. *See*, for example, Keppler *et al.*, *Glycobiology* **11**: 11R (2001); and Charter *et al.*, *Glycobiology* **10**: 1049 (2000)). Other amine reactive polymeric modifying moiety precursors and components, e.g., PEG and PPG analogues are commercially available, or they can be prepared by methods readily accessible to those of skill in the art.

Table 1



in which R is the polymeric (branched or straight-chain) modifying moiety.

[0192] The modified sugar phosphates of use in practicing the present invention can be substituted in other positions as well as those set forth above. Presently preferred substitutions of sialic acid are set forth in the formula below:



in which one or more of X^c , Y^a , Y^b , Y^c and Z is a linking group, which is preferably selected from $-O-$, $-N(H)-$, $-S$, CH_2- , and $N(R)_2$. When X^c , Y^a , Y^b , Y^c and Z is a linking group, it is attached to the polymeric modifying moiety as represented by R^c , R^d , R^e , R^f and R^g .

Alternatively, these symbols represent a linker that is bound to a branched- or straight-chain water-soluble or water-insoluble polymer, therapeutic moiety, biomolecule or other moiety. When R^c , R^d , R^e , R^f or R^g is not a polymeric modifying moiety, the combination of X^cR^c , Y^aR^d , Y^bR^e , Y^cR^f or ZR^g is H, OH or $NC(O)CH_3$.

[0193] Also provided is a synthetic method for producing an activated sialic acid-polymeric modifying group conjugate that is an appropriate substrate for an enzyme that transfers the modified sugar moiety onto an acceptor, e.g., a glycosyltransferase. The method includes the steps: (a) contacting mannosamine with an activated, N-protected amino acid (or an amino acid functionalized with a polymeric modifying moiety, a linker precursor or a linker-polymeric modifying moiety cassette) under conditions appropriate to form an amide conjugate between the mannosamine and the N-protected amino acid; (b) contacting the amide conjugate with pyruvate and sialic acid aldolase under conditions appropriate to convert the amide conjugate to a sialic acid amide conjugate; (c) contacting the sialic acid amide conjugate with cytidine triphosphates, and a synthetase under conditions appropriate to form a cytidine monophosphate sialic acid amide conjugate; (d) removing the N-protecting group from the cytidine monophosphate sialic acid amide conjugate, thereby producing a free amine; and (e) contacting the free amine with an activated PEG (straight-chain or branched), thereby forming the cytidine monophosphate sialic acid-poly(ethylene glycol).

Cross-linking Groups

[0194] Preparation of the modified sugar for use in the methods of the present invention includes attachment of a modifying group to a sugar residue and forming a stable adduct,

which is a substrate for a glycosyltransferase. The sugar and modifying group can be coupled by a zero- or higher-order cross-linking agent. Exemplary bifunctional compounds which can be used for attaching modifying groups to carbohydrate moieties include, but are not limited to, bifunctional poly(ethyleneglycols), polyamides, polyethers, polyesters and the like. General approaches for linking carbohydrates to other molecules are known in the literature. See, for example, Lee *et al.*, *Biochemistry* **28**: 1856 (1989); Bhatia *et al.*, *Anal. Biochem.* **178**: 408 (1989); Janda *et al.*, *J. Am. Chem. Soc.* **112**: 8886 (1990) and Bednarski *et al.*, WO 92/18135. In the discussion that follows, the reactive groups are treated as benign on the sugar moiety of the nascent modified sugar. The focus of the discussion is for clarity of illustration. Those of skill in the art will appreciate that the discussion is relevant to reactive groups on the modifying group as well.

[0195] An exemplary strategy involves incorporation of a protected sulfhydryl onto the sugar using the heterobifunctional crosslinker SPDP (n-succinimidyl-3-(2-pyridyldithio)propionate and then deprotecting the sulfhydryl for formation of a disulfide bond with another sulfhydryl on the modifying group.

[0196] A variety of reagents are used to modify the components of the modified sugar with intramolecular chemical crosslinks (for reviews of crosslinking reagents and crosslinking procedures see: Wold, F., *Meth. Enzymol.* **25**: 623-651, 1972; Weetall, H. H., and Cooney, D. A., In: *ENZYMES AS DRUGS*. (Holcenberg, and Roberts, eds.) pp. 395-442, Wiley, New York, 1981; Ji, T. H., *Meth. Enzymol.* **91**: 580-609, 1983; Mattson *et al.*, *Mol. Biol. Rep.* **17**: 167-183, 1993, all of which are incorporated herein by reference). Preferred crosslinking reagents are derived from various zero-length, homo-bifunctional, and hetero-bifunctional crosslinking reagents. Zero-length crosslinking reagents include direct conjugation of two intrinsic chemical groups with no introduction of extrinsic material.

Conjugation of Modified Sugars to Peptides

[0197] The modified sugars are conjugated to a glycosylated or non-glycosylated peptide using an appropriate enzyme to mediate the conjugation. Thus, the compounds of the invention, particularly the nucleotide sugars are preferably substrates for enzymes that transfer sugar moieties from a nucleotide sugar onto an amino acid, glycosyl, or aglycone acceptor moiety. Nucleotide sugars that act as sugar donors for acceptors, e.g., galactosyl acceptors, e.g., GalNAc, Gal β 1,4GlcNAc, Gal β 1,4GalNAc, Gal β 1,3GalNAc, lacto-N-tetraose, Gal β 1,3GlcNAc, Gal β 1,3Ara, Gal β 1,6GlcNAc, Gal β 1,4Glc (lactose), and other

acceptors well known to those of skill in the art (*see, e.g., Paulson et al., J. Biol. Chem.* **253**: 5617-5624 (1978)).

[0198] Exemplary enzymes for which the modified nucleotide sugars of the invention are substrates include glycosyltransferases. The glycosyltransferase can be cloned, or isolated from any source. Many cloned glycosyltransferases are known, as are their polynucleotide sequences. *See, e.g., "The WWW Guide To Cloned Glycosyltransferases,"* (http://www.vei.co.uk/TGN/gt_guide.htm). Glycosyltransferase amino acid sequences and nucleotide sequences encoding glycosyltransferases from which the amino acid sequences can be deduced are also found in various publicly available databases, including GenBank, Swiss-Prot, EMBL, and others.

[0199] Glycosyltransferases for which the compounds of the invention are substrates include, but are not limited to, galactosyltransferases, fucosyltransferases, glucosyltransferases, N-acetylgalactosaminyltransferases, N-acetylglucosaminyltransferases, glucuronyltransferases, sialyltransferases, mannosyltransferases, glucuronic acid transferases, galacturonic acid transferases, and oligosaccharyltransferases. Suitable glycosyltransferases include those obtained from eukaryotes, as well as from prokaryotes.

[0200] In some embodiments, the compound of the invention is a substrate for a fucosyltransferase. Fucosyltransferases are generally known to those of skill in the art, and are exemplified by enzymes that transfer L-fucose from GDP-fucose to a hydroxy position of an acceptor sugar.

[0201] In another group of embodiments, the compound is a substrate for a galactosyltransferase. Exemplary galactosyltransferases include $\alpha(1,3)$ galactosyltransferases (E.C. No. 2.4.1.151, *see, e.g., Dabkowski et al., Transplant Proc.* **25**:2921 (1993) and Yamamoto *et al. Nature* **345**: 229-233 (1990), bovine (GenBank j04989, Joziase *et al., J. Biol. Chem.* **264**: 14290-14297 (1989)), murine (GenBank m26925; Larsen *et al., Proc. Nat'l. Acad. Sci. USA* **86**: 8227-8231 (1989)), porcine (GenBank L36152; Strahan *et al., Immunogenetics* **41**: 101-105 (1995)). Another suitable $\alpha(1,3)$ galactosyltransferase is that which is involved in synthesis of the blood group B antigen (EC 2.4.1.37, Yamamoto *et al., J. Biol. Chem.* **265**: 1146-1151 (1990) (human)). Yet a further exemplary galactosyltransferase is core Gal-T1. Still further examples include $\beta(1,4)$ galactosyltransferases, which include, for example, EC 2.4.1.90 (LacNAc synthetase) and EC 2.4.1.22 (lactose synthetase) (bovine (D'Agostaro *et al., Eur. J. Biochem.* **183**: 211-217 (1989)), human (Masri *et al., Biochem.*

Biophys. Res. Commun. **157**: 657-663 (1988)), murine (Nakazawa *et al.*, *J. Biochem.* **104**: 165-168 (1988)), as well as E.C. 2.4.1.38 and the ceramide galactosyltransferase (EC 2.4.1.45, Stahl *et al.*, *J. Neurosci. Res.* **38**: 234-242 (1994)). Other suitable galactosyltransferases include, for example, α 1,2 galactosyltransferases (from *e.g.*, *Schizosaccharomyces pombe*, Chapell *et al.*, *Mol. Biol. Cell* **5**: 519-528 (1994)). Also suitable in the practice of the invention are soluble forms of α 1, 3- galactosyltransferase such as that reported by Cho *et al.*, *J. Biol. Chem.*, **272**: 13622-13628 (1997).

a) Sialyltransferases

[0202] Sialyltransferases are another type of glycosyltransferase for which the compounds of the invention are substrates. Examples include ST3Gal III (*e.g.*, a rat or human ST3Gal III), ST3Gal IV, ST3Gal I, ST6Gal I, ST3Gal V, ST6Gal II, ST6GalNAc I, ST6GalNAc II, and ST6GalNAc III (the sialyltransferase nomenclature used herein is as described in Tsuji *et al.*, *Glycobiology* **6**: v-xiv (1996)). An exemplary α (2,3)sialyltransferase referred to as α (2,3)sialyltransferase (EC 2.4.99.6) transfers sialic acid to the non-reducing terminal Gal of a Gal β 1 \rightarrow 3Glc disaccharide or glycoside. *See*, Van den Eijnden *et al.*, *J. Biol. Chem.* **256**: 3159 (1981), Weinstein *et al.*, *J. Biol. Chem.* **257**: 13845 (1982) and Wen *et al.*, *J. Biol. Chem.* **267**: 21011 (1992). Another exemplary α 2,3-sialyltransferase (EC 2.4.99.4) transfers sialic acid to the non-reducing terminal Gal of the disaccharide or glycoside. *see*, Rearick *et al.*, *J. Biol. Chem.* **254**: 4444 (1979) and Gillespie *et al.*, *J. Biol. Chem.* **267**: 21004 (1992). Further exemplary enzymes include Gal- β -1,4-GlcNAc α -2,6 sialyltransferase (*See*, Kurosawa *et al.*, *Eur. J. Biochem.* **219**: 375-381 (1994)). Other sialyltransferases for which the compounds of the invention are substrates include those that form polysialic acids. Examples include the α -2,8-polysialyltransferases, *e.g.*, ST8SiaI, ST8SiaII, ST8SiaIII, ST8SiaIV and ST8SiaV. *See for example*, Angata *et al.*, *J. Biol. Chem.* **275**: 18594-18601 (2000); Kono *et al.*, *J. Biol. Chem.* **271**: 29366-29371 (1996); Greiner *et al.*, *Infect. Immun.* **72**: 4249-4260 (2004); and Jones *et al.*, *J. Biol. Chem.* **277**: 14598-14611 (2002).

[0203] An example of a sialyltransferase that is useful in the claimed methods is ST3Gal III, which is also referred to as α (2,3)sialyltransferase (EC 2.4.99.6). This enzyme catalyzes the transfer of sialic acid to the Gal of a Gal β 1,3GlcNAc or Gal β 1,4GlcNAc glycoside (*see, e.g.*, Wen *et al.*, *J. Biol. Chem.* **267**: 21011 (1992); Van den Eijnden *et al.*, *J. Biol. Chem.*

256: 3159 (1991)). Still further sialyltransferases include those isolated from *Campylobacter jejuni*, including the $\alpha(2,3)$. See, e.g, WO99/49051.

[0204] Preferably, the compounds of the invention are substrates for an enzyme that transfers the modifies sialic acid to the sequence Gal β 1,4GlcNAc-, the most common penultimate sequence underlying the terminal sialic acid on fully sialylated carbohydrate structures.

b) GalNAc transferases

[0205] Selected compounds of the invention are substrates for N-acetylgalactosaminyltransferases. Exemplary N-acetylgalactosaminyltransferases include, but are not limited to, $\alpha(1,3)$ N-acetylgalactosaminyltransferase, $\beta(1,4)$ N-acetylgalactosaminyltransferases (Nagata *et al.*, *J. Biol. Chem.* **267**: 12082-12089 (1992) and Smith *et al.*, *J. Biol. Chem.* **269**: 15162 (1994)) and polypeptide N-acetylgalactosaminyltransferase (Homa *et al.*, *J. Biol. Chem.* **268**: 12609 (1993)).

c) Glycosidases

[0206] This invention also encompasses substrates for wild-type and mutant glycosidases. Mutant β -galactosidase enzymes have been demonstrated to catalyze the formation of disaccharides through the coupling of α -glycosyl fluoride to a galactosyl acceptor molecule. (Withers, U.S. Pat. No. 6,284,494; issued Sept. 4, 2001). Other glycosidases of use in this invention include, for example, β -glucosidases, β -galactosidases, β -mannosidases, β -acetyl glucosaminidases, β -N-acetyl galactosaminidases, β -xylosidases, β -fucosidases, cellulases, xylanases, galactanases, mannanases, hemicellulases, amylases, glucoamylases, α -glucosidases, α -galactosidases, α -mannosidases, α -N-acetyl glucosaminidases, α -N-acetyl galactose-aminidases, α -xylosidases, α -fucosidases, and neuraminidases/sialidases, endoglycoceramidases.

[0207] The following examples are provided to illustrate selected embodiments of the invention and are not to be construed as limiting its scope.

EXAMPLES

Example 1

Preparation of UDP-GalNAc-6'-CHO

[0344] UDP-GalNAc (200 mg, 0.30 mmoles) was dissolved in a 1 mM CuSO₄ solution (20 mL) and a 25 mM NaH₂PO₄ solution (pH 6.0; 20 mL). Galactose oxidase (240 U; 240 µL) and catalase (13000 U; 130 µL) were then added, the reaction system equipped with a balloon filled with oxygen and stirred at room temperature for seven days. The reaction mixture was then filtered (spin cartridge; MWCO 5K) and the filtrate (~40 mL) was stored at 4° C until required. TLC (silica; EtOH/water (7/2); R_f = 0.77; visualized with anisaldehyde stain).

Example 2


Preparation of UDP-GalNAc-6'-NH₂):

[0345] Ammonium acetate (15 mg, 0.194 mmoles) and NaBH₃CN (1M THF solution; 0.17 mL, 0.17 mmoles) were added to the UDP-GalNAc-6'-CHO solution from above (2 mL or ~ 20 mg) at 0°C and allowed to warm to room temperature overnight. The reaction was filtered through a G-10 column with water and the product collected. The appropriate fractions were freeze-dried and stored frozen. TLC (silica; ethanol/water (7/2); R_f = 0.72; visualized with ninhydrin reagent).

Example 3

Preparation of UDP-GalNAc-6-NHCO(CH₂)₂-O-PEG-OMe (1 KDa).

[0346] The galactosaminy-1-phosphate-2-NHCO(CH₂)₂-O-PEG-OMe (1 KDa) (58 mg, 0.045 mmoles) was dissolved in DMF (6 mL) and pyridine (1.2 mL). UMP-morpholidate (60 mg, 0.15 mmoles) was then added and the resulting mixture stirred at 70°C for 48 h. The solvent was removed by bubbling nitrogen through the reaction mixture and the residue purified by reversed phase chromatography (C-18 silica, step gradient between 10 to 80%, methanol/water). The desired fractions were collected and dried at reduced pressure to yield a white solid. TLC (silica, propanol/H₂O/NH₄OH, (30/20/2), R_f = 0.54). MS (MALDI): Observed, 1485, 1529, 1618, 1706.

Example 4**Preparation of Cysteine-PEG₂ (2)***4.1 Synthesis of Compound 1*

[0347] Potassium hydroxide (84.2 mg, 1.5 mmol, as a powder) was added to a solution of L-cysteine (93.7mg, 0.75 mmol) in anhydrous methanol (20L) under argon. The mixture was stirred at room temperature for 30 min, and then mPEG-O-tosylate of molecular mass 20 kilodalton (Ts; 1.0 g, 0.05 mmol) was added in several portions over 2 hours. The mixture was stirred at room temperature for 5 days, and concentrated by rotary evaporation. The residue was diluted with water (30 mL), and stirred at room temperature for 2 hours to destroy any excess 20 kilodalton mPEG- O-tosylate. The solution was then neutralized with acetic acid, the pH adjusted to pH 5.0 and loaded onto a reversed phase chromatography (C-18 silica) column. The column was eluted with a gradient of methanol/water (the product elutes at about 70% methanol), product elution monitored by evaporative light scattering, and the appropriate fractions collected and diluted with water (500 mL). This solution was chromatographed (ion exchange, XK 50 Q, BIG Beads, 300 ml, hydroxide form; gradient of water to water/acetic acid-0.75N) and the pH of the appropriate fractions lowered to 6.0 with acetic acid. This solution was then captured on a reversed phase column (C-18 silica) and eluted with a gradient of methanol/water as described above. The product fractions were pooled, concentrated, redissolved in water and freeze-dried to afford a white solid (1). Structural data for the compound were as follows: ¹H-NMR (500 MHz; D₂O) δ 2.83 (t, 2H, O-C-CH₂-S), 3.05 (q, 1H, S-CH₂-CHN), 3.18 (q, 1H, (q, 1H, S-CH₂-CHN), 3.38 (s, 3H, CH₃O), 3.7 (t, OCH₂CH₂O), 3.95 (q, 1H, CHN). The purity of the product was confirmed by SDS PAGE.

4.2 Synthesis of Compound 2 (Cysteine-PEG₂)

[0348] Triethylamine (~0.5 mL) was added dropwise to a solution of compound 1 (440 mg, 22 μ mol) dissolved in anhydrous CH₂Cl₂ (30 mL) until the solution was basic. A solution of 20 kilodalton mPEG-O-p-nitrophenyl carbonate (660 mg, 33 μ mol) and N-hydroxysuccinimide (3.6 mg, 30.8 μ mol) in CH₂Cl₂ (20 mL) was added in several portions over 1 hour at room temperature. The reaction mixture was stirred at room temperature for 24 hours. The solvent was then removed by rotary evaporation, the residue was dissolved in water (100 mL), and the pH adjusted to 9.5 with 1.0 N NaOH. The basic solution was stirred at room temperature for 2 hours and was then neutralized with acetic acid to a pH 7.0. The solution was then loaded onto a reversed phase chromatography (C-18 silica) column. The column was eluted with a gradient of methanol/water (the product elutes at about 70% methanol), product elution monitored by evaporative light scattering, and the appropriate fractions collected and diluted with water (500 mL). This solution was chromatographed (ion exchange, XK 50 Q, BIG Beads, 300 mL, hydroxide form; gradient of water to water/acetic acid-0.75N) and the pH of the appropriate fractions lowered to 6.0 with acetic acid. This solution was then captured on a reversed phase column (C-18 silica) and eluted with a gradient of methanol/water as described above. The product fractions were pooled, concentrated, redissolved in water and freeze-dried to afford a white solid (2). Structural data for the compound were as follows: ¹H-NMR (500 MHz; D₂O) δ 2.83 (t, 2H, O-C-CH₂-S), 2.95 (t, 2H, O-C-CH₂-S), 3.12 (q, 1H, S-CHH-CHN), 3.39 (s, 3H CH₃O), 3.71 (t, OCH₂CH₂O). The purity of the product was confirmed by SDS PAGE.

Example 5

Preparation of UDP-GalNAc-6-NHCO(CH₂)₂-O-PEG-OMe (1 KDa).

[0349] Galactosaminy-1-phosphate-2-NHCO(CH₂)₂-O-PEG-OMe (1 kilodalton) (58 mg, 0.045 mmoles) was dissolved in DMF (6 mL) and pyridine (1.2 mL). UMP-morpholidate (60 mg, 0.15 mmoles) was then added and the resulting mixture stirred at 70°C for 48 h. The solvent was removed by bubbling nitrogen through the reaction mixture and the residue purified by reversed phase chromatography (C-18 silica, step gradient between 10 to 80%, methanol/water). The desired fractions were collected and dried at reduced pressure to yield a white solid. TLC (silica, propanol/H₂O/NH₄OH, (30/20/2), R_f = 0.54). MS (MALDI): Observed, 1485, 1529, 1618, 1706.

SDS PAGE Procedure


[0208] The purity of the products, 1 and 2, were confirmed by SDS PAGE. A 4-20% Tris-Glycine SDS PAGE gel (Invitrogen) was used. The sample was mixed 1:1 with SDS Sample Buffer, and was run in Tris-Glycine Running Buffer (LC2675-5) at a constant voltage (125 V) for 1 hr 50 min. After electrophoresis, the gel was washed with water (100 mL) for 10 min followed by a wash with a 5% barium chloride aqueous solution (100 mL) for 10 min. Products 1 or 2 were visualized by staining the gels with 0.1 N iodine solution (4.0 mL) at room temperature and the staining process stopped by washing the gels with water. The visualized product bands were scanned with an HP Scanjet 7400C, and the image of the gel was optimized with the HP Precision Scan Program.

[0209] While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention.

[0210] All patents, patent applications, and other publications cited in this application are incorporated by reference herein in their entirety for all purposes.

WHAT IS CLAIMED IS:

1. A compound having a formula that is a member selected from:



wherein

R^1 is H, CH_2OR^7 , COOR^7 or OR^7

in which

R^7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;

R^2 is a member selected from H, OH, an activating group and a moiety that includes a nucleotide;


R^3 , R^4 , R^5 , R^6 and $R^{6'}$ are independently selected from H, substituted or unsubstituted alkyl, OR^9 , and $\text{NHC}(\text{O})\text{R}^{10}$

wherein

R^9 and R^{10} are independently selected from H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl,

and at least one of R^3 , R^4 , R^5 , R^6 and $R^{6'}$ includes a polymeric modifying moiety.


2. The compound according to claim 1 wherein R^2 has the formula:



in which R^8 is a nucleoside.

3. The compound according to claim 2 wherein R^8 is a member selected from cytosine, uridine, guanosine, adenosine and thymidine.

4. The compound according to claim 1 wherein at least one of R^3 , R^4 , R^5 and R^6 includes the moiety:



wherein


R^{11} is a polymeric modifying moiety;

L is a member selected from a bond and a linking group; and


w is selected from the integers from 1 to 6.

5. The compound according to claim 4 wherein said linking group is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl moieties.

6. The compound according to claim 5 wherein the moiety:



has the formula:



wherein


X^2 and X^4 are independently selected from linkage fragments;

X^a is a linkage fragment;

R^{12} and R^{13} are independently selected polymeric arms; and

c is an integer from 1 to 20.

7. The compound according to claim 5 wherein said linking group has the formula:



in which


X^a and X^b are independently selected linkage fragments; and

L^1 is a member selected from a bond, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.

8. The compound according to claim 7 wherein X^a and X^b are linkage fragments independently selected from S, SC(O)NH, HNC(O)S, SC(O)O, O, NH, NHC(O), (O)CNH and NHC(O)O, and OC(O)NH.

9. The compound according to claim 5 wherein said linker comprises an acyl moiety.

10. The compound according to claim 9 wherein $L-R^{11}$ has the formula:




in which

s is an integer from 0 to 20; and

R^{11} is said polymeric modifying moiety.

11. The compound according to claim 1, wherein said polymeric modifying moiety has the formula:



wherein

X^2 and X^4 are independently selected from linkage fragments;

X^5 is a non-reactive group; and

R^{12} and R^{13} are independently selected polymeric arms.

12. The compound according to claim 11 wherein X^2 and X^4 are linkage fragments independently selected from S, SC(O)NH, HNC(O)S, SC(O)O, O, NH, NHC(O), (O)CNH and NHC(O)O, OC(O)NH and $(\text{CH}_2)_g Y''$

wherein

g is an integer from 1 to 50; and


Y'' is a member selected from O, S and NH.

13. The compound according to claim 11 wherein

X^4 is a peptide bond; and

R^{13} is an amino acid residue.

14. The compound according to claim 1 having the formula:



in which



D is a member selected from -OH and $(R^{11})_{w'}-L-$;

G represents is a member selected from H, $(R^{11})_{w'}-L-$ and $-C(O)(C_1-C_6)alkyl$;

w' is an integer from 2 to 6, and

at least one of D and G is $(R^{11})_{w'}-L-$.



15. The compound according to claim 14 having the formula:



wherein

L^a is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.

16. The compound according to claim 1 having the formula:



wherein


L^a is a member selected from an amino acid residue and a peptidyl residue having from 2 to 4 amino acid residues;

X^2 and X^4 are independently selected from linkage fragments;

X^5 is a non-reactive group; and

R^{12} and R^{13} are independently selected polymeric arms

17. The compound according to claim 16 having the formula:



wherein


X^2 and X^4 are independently selected from linkage fragments;

X^a is a linkage fragment;

R^{12} and R^{13} are independently selected polymeric arms; and

c is an integer from 1 to 20.

18. The compound according to claim 1, having the formula:



wherein

AA-NH is an amino acid residue; and

P is a polymeric modifying group.

19. The compound according to claim 18 wherein -AA-NH is -CH₂NH.

20. The compound according to claim 1 wherein said compound is a substrate for an enzyme that transfers a sugar moiety from a member selected from an activated sugar, a nucleotide sugar and combinations thereof onto an acceptor moiety of a substrate.

21. The compound according to claim 20 wherein said acceptor moiety is a member selected from a glycosyl residue, an amino acid residue and an aglycone.

22. A method of preparing cytidine monophosphate sialic acid-poly(ethylene glycol), said method comprising:

(a) contacting mannosamine with an activated, N-protected amino acid under conditions appropriate to form an amide conjugate between said mannosamine and the N-protected amino acid;

(b) contacting said amide conjugate with pyruvate and sialic acid aldolase under conditions appropriate to convert said amide conjugate to a sialic acid amide conjugate;

(c) contacting said sialic acid amide conjugate with cytidine triphosphates, and a synthetase under conditions appropriate to form a cytidine monophosphate sialic acid amide conjugate;

(d) removing the N-protecting group from said cytidine monophosphate sialic acid amide conjugate, thereby producing a free amine; and

(e) contacting said free amine with an activated PEG, thereby forming said cytidine monophosphate sialic acid-poly(ethylene glycol).

23. The method according to claim 21, wherein said activated N-protected amino acid has the formula:




FIGURE 1A

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
At1g08280	<i>Arabidopsis thaliana</i>	n.d.	AC011438 AAF18241.1 BT004583 AAO42829.1 NC_003070 NP_172305.1	Q84W00 Q9SGD2	
At1g08660/F22O13.14	<i>Arabidopsis thaliana</i>	n.d.	AC003981 AAF99778.1 AY064135 AAL36042.1 AY124807 AAM70516.1 NC_003070 NP_172342.1 NM_180609 NP_850940.1	Q8VZJ0 Q9FRR9	
At3g48820/T21J18_90	<i>Arabidopsis thaliana</i>	n.d.	AY080589 AAL85966.1 AY133816 AAM91750.1 AL132963 CAB87910.1 NM_114741 NP_190451.1	Q8RY00 Q9M301	
α -2,3-sialyltransferase (ST3Gal-IV)	<i>Bos taurus</i>	n.d.	AJ584673 CAE48298.1		
α -2,3-sialyltransferase (ST3Gal-V)	<i>Bos taurus</i>	n.d.	AJ585768 CAE51392.1		
α -2,6-sialyltransferase (Siat7b)	<i>Bos taurus</i>	n.d.	AJ620651 CAF05850.1		
α -2,8-sialyltransferase (SIAT8A)	<i>Bos taurus</i>	2.4.99.8	AJ699418 CAG27880.1		
α -2,8-sialyltransferase (Siat8D)	<i>Bos taurus</i>	n.d.	AJ699421 CAG27883.1		
α -2,8-sialyltransferase ST8Sia-III (Siat8C)	<i>Bos taurus</i>	n.d.	AJ704563 CAG28696.1		
CMP α -2,6-sialyltransferase (ST6Gal I)	<i>Bos taurus</i>	2.4.99.1	Y15111 CAA75385.1 NM_177517 NP_803483.1	O18974	
sialyltransferase 8 (fragment)	<i>Bos taurus</i>	n.d.	AF450088 AAL47018.1	Q8WN13	
sialyltransferase ST3Gal-II (Siat4B)	<i>Bos taurus</i>	n.d.	AJ748841 CAG44450.1		
sialyltransferase ST3Gal-III (Siat6)	<i>Bos taurus</i>	n.d.	AJ748842 CAG44451.1		
sialyltransferase ST3Gal-VI (Siat10)	<i>Bos taurus</i>	n.d.	AJ748843 CAG44452.1		
ST3Gal I	<i>Bos taurus</i>	n.d.	AJ305086 CAC24698.1	Q9BEG4	
St6GalNAc-VI	<i>Bos taurus</i>	n.d.	AJ620949 CAF06586.1		
CDS4	<i>Branchiostoma floridae</i>	n.d.	AF391289 AAM18873.1	Q8T771	
polysialyltransferase (PST) (fragment) ST8Sia IV	<i>Cercopithecus aethiops</i>	2.4.99.-	AF210729 AAF17105.1	Q9TT09	
polysialyltransferase (STX) (fragment) ST8Sia II	<i>Cercopithecus aethiops</i>	2.4.99.-	AF210318 AAF17104.1	Q9TT10	
α -2,3-sialyltransferase ST3Gal I (Siat4)	<i>Ciona intestinalis</i>	n.d.	AJ626815 CAF25173.1		
α -2,3-sialyltransferase ST3Gal I (Siat4)	<i>Ciona savignyi</i>	n.d.	AJ626814 CAF25172.1		
α -2,8-polysialyltransferase ST8Sia IV	<i>Cricetulus griseus</i>	2.4.99.-	-AAE28634 Z46801 CAA86822.1	Q64690	
Gal β -1,3/4-GlcNAc α -2,3-sialyltransferase ST3Gal I	<i>Cricetulus griseus</i>	n.d.	AY266675 AAP22942.1	Q80WL0	
Gal β -1,3/4-GlcNAc α -2,3-sialyltransferase ST3Gal II (fragment)	<i>Cricetulus griseus</i>	n.d.	AY266676 AAP22943.1	Q80WK9	
α -2,3-sialyltransferase ST3Gal I (Siat4)	<i>Danio rerio</i>	n.d.	AJ783740 CAH04017.1		
α -2,3-sialyltransferase ST3Gal II (Siat5)	<i>Danio rerio</i>	n.d.	AJ783741 CAH04018.1		
α -2,3-sialyltransferase ST3Gal III (Siat6)	<i>Danio rerio</i>	n.d.	AJ626821 CAF25179.1		
α -2,3-sialyltransferase ST3Gal IV (Siat4c)	<i>Danio rerio</i>	n.d.	AJ744809 CAG32845.1		

FIGURE 1B

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
α -2,3-sialyltransferase ST3Gal V-r (Siat5-related)	<i>Danio rerio</i>	n.d.	AJ783742 CAH04019.1		
α -2,6-sialyltransferase ST6Gal I (Siat1)	<i>Danio rerio</i>	n.d.	AJ744801 CAG32837.1		
α -2,6-sialyltransferase ST6GalNAc II (Siat7B)	<i>Danio rerio</i>	n.d.	AJ634459 CAG25680.1		
α -2,6-sialyltransferase ST6GalNAc V (Siat7E) (fragment)	<i>Danio rerio</i>	n.d.	AJ646874 CAG26703.1		
α -2,6-sialyltransferase ST6GalNAc VI (Siat7F) (fragment)	<i>Danio rerio</i>	n.d.	AJ646883 CAG26712.1		
α -2,8-sialyltransferase ST8Sia I (Siat 8A) (fragment)	<i>Danio rerio</i>	n.d.	AJ715535 CAG29374.1		
α -2,8-sialyltransferase ST8Sia III (Siat 8C) (fragment)	<i>Danio rerio</i>	n.d.	AJ715543 CAG29382.1		
α -2,8-sialyltransferase ST8Sia IV (Siat 8D) (fragment)	<i>Danio rerio</i>	n.d.	AJ715545 CAG29384.1		
α -2,8-sialyltransferase ST8Sia V (Siat 8E) (fragment)	<i>Danio rerio</i>	n.d.	AJ715546 CAG29385.1		
α -2,8-sialyltransferase ST8Sia VI (Siat 8F) (fragment)	<i>Danio rerio</i>	n.d.	AJ715551 CAG29390.1		
β -galactosamide α -2,6- sialyltransferase II (ST6Gal II)	<i>Danio rerio</i>	n.d.	AJ627627 CAF29495.1		
N-glycan α -2,8- sialyltransferase	<i>Danio rerio</i>	n.d.	BC050483 AAH50483.1 AY055462 AAL17875.1 NM_153662 NP_705948.1	Q7ZU51 Q8QH83	
ST3Gal III-related (sial6r)	<i>Danio rerio</i>	n.d.	BC053179 AAH53179.1 AJ626820 CAF25178.1 NM_200355 NP_956649.1	Q7T3B9	
St3Gal-V	<i>Danio rerio</i>	n.d.	AJ619960 CAF04061.1		
st6GalNAc-VI	<i>Danio rerio</i>	n.d.	BC060932 AAH60932.1 AJ620947 CAF06584.1		
α -2,6-sialyltransferase (CG4871) ST6Gal I	<i>Drosophila melanogaster</i>	2.4.99.1	AE003465 AAF47256.1 AF218237 AAG13185.1 AF397532 AAK92126.1 AE003465 AAM70791.1 NM_079129 NP_523853.1 NM_166684 NP_726474.1	Q9GU23 Q9W121	
α -2,3-sialyltransferase (ST3Gal-VI)	<i>Gallus gallus</i>	n.d.	AJ585767 CAE51391.1 AJ627204 CAF25503.1		
α -2,3-sialyltransferase ST3Gal I	<i>Gallus gallus</i>	2.4.99.4	X80503 CAA56666.1 NM_205217 NP_990548.1	Q11200	
α -2,3-sialyltransferase ST3Gal IV (fragment)	<i>Gallus gallus</i>	2.4.99.-	AF035250 AAC14163.1	O73724	
α -2,3-sialyltransferase (ST3GAL-II)	<i>Gallus gallus</i>	n.d.	AJ585761 CAE51385.2		
α -2,6-sialyltransferase (Siat7b)	<i>Gallus gallus</i>	n.d.	AJ620653 CAF05852.1		
α -2,6-sialyltransferase ST6Gal I	<i>Gallus gallus</i>	2.4.99.1	X75558 CAA53235.1 NM_205241 NP_990572.1	Q92182	
α -2,6-sialyltransferase ST6GalNAc I	<i>Gallus gallus</i>	2.4.99.3	-AAE68028.1 -AAE68029.1 X74946 CAA52902.1 NM_205240 NP_990571.1	Q92183	
α -2,6-sialyltransferase ST6GalNAc II	<i>Gallus gallus</i>	2.4.99.-	X77775 AAE68030.1 NM_205233 CAA54813.1 NP_990564.1	Q92184	
α -2,6-sialyltransferase ST6GalNAc III (SIAT7C)	<i>Gallus gallus</i>	n.d.	AJ634455 CAG25677.1		

FIGURE 1C

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
(fragment) α -2,6-sialyltransferase ST6GalNAc V (SIAT7E)	<i>Gallus gallus</i>	n.d.	AJ646877 CAG26706.1		
(fragment) α -2,8-sialyltransferase (GD3 Synthase) ST8Sia I	<i>Gallus gallus</i>	2.4.99.-	U73176 AAC28888.1	P79783	
α -2,8-sialyltransferase (SIAT8B)	<i>Gallus gallus</i>	n.d.	AJ699419 CAG27881.1		
α -2,8-sialyltransferase (SIAT8C)	<i>Gallus gallus</i>	n.d.	AJ699420 CAG27882.1		
α -2,8-sialyltransferase (SIAT8F)	<i>Gallus gallus</i>	n.d.	AJ699424 CAG27886.1		
α -2,8-sialyltransferase ST8Sia-V (SIAT8C)	<i>Gallus gallus</i>	n.d.	AJ704564 CAG28697.1		
β -galactosamide α -2,6- sialyltransferase II (ST6Gal II)	<i>Gallus gallus</i>	n.d.	AJ627629 CAF29497.1		
GM3 synthase (SIAT9)	<i>Gallus gallus</i>	2.4.99.9	AY515255 AAS83519.1		
polysialyltransferase ST8Sia IV	<i>Gallus gallus</i>	2.4.99.-	AF008194 AAB95120.1	O42399	
α -2,3-sialyltransferase ST3Gal I	<i>Homo sapiens</i>	2.4.99.4	L29555 AAA36612.1 AF059321 AAC17874.1 L13972 AAC37574.1 AF155238 AAD39238.1 AF186191 AAG29876.1 BC018357 AAH18357.1 NM_003033 NP_003024.1 NM_173344 NP_775479.1	Q11201 O60677 Q9UN51	
α -2,3-sialyltransferase ST3Gal II	<i>Homo sapiens</i>	2.4.99.4	U63090 AAB40389.1 BC036777 AAH36777.1 X96667 CAA65447.1 NM_006927 NP_008858.1	Q16842 O00654	
α -2,3-sialyltransferase ST3Gal III (SiaT6)	<i>Homo sapiens</i>	2.4.99.6	L23768 AAA35778.1 BC050380 AAH50380.1 AF425851 AAO13859.1 AF425852 AAO13860.1 AF425853 AAO13861.1 AF425854 AAO13862.1 AF425855 AAO13863.1 AF425856 AAO13864.1 AF425857 AAO13865.1 AF425858 AAO13866.1 AF425859 AAO13867.1 AF425860 AAO13868.1 AF425861 AAO13869.1 AF425862 AAO13870.1 AF425863 AAO13871.1 AF425864 AAO13872.1 AF425865 AAO13873.1 AF425866 AAO13874.1 AF425867 AAO13875.1 AY167992 AAO38806.1 AY167993 AAO38807.1 AY167994 AAO38808.1 AY167995 AAO38809.1 AY167996 AAO38810.1 AY167997 AAO38811.1 AY167998 AAO38812.1 NM_006279 NP_006270.1 NM_174964 NP_777624.1 NM_174965 NP_777625.1 NM_174966 NP_777626.1 NM_174967 NP_777627.1 NM_174969 NP_777629.1 NM_174970 NP_777630.1 NM_174972 NP_777632.1	Q11203 Q86UR6 Q86UR7 Q86UR8 Q86UR9 Q86US0 Q86US1 Q86US2 Q8IX43 Q8IX44 Q8IX45 Q8IX46 Q8IX47 Q8IX48 Q8IX49 Q8IX50 Q8IX51 Q8IX52 Q8IX53 Q8IX54 Q8IX55 Q8IX56 Q8IX57 Q8IX58	

FIGURE 1D

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
α -2,3-sialyltransferase ST3Gal IV	<i>Homo sapiens</i>	2.4.99.-	L23767 AAA16460.1 AF035249 AAC14162.1 BC010645 AAH10645.1 AY040826 AAK93790.1 AF516602 AAM66431.1 AF516603 AAM66432.1 AF516604 AAM66433.1 AF525084 AAM81378.1 X74570 CAA52662.1 CR456858 CAG33139.1 NM_006278 NP_006269.1	Q11206 O60497 Q96QQ9 Q8N6A6 Q8N6A7 Q8NFD3 Q8NFG7	
α -2,3-sialyltransferase ST3Gal VI	<i>Homo sapiens</i>	2.4.99.4	AF119391 AAD39131.1 BC023312 AAH23312.1 AB022918 BAA77609.1 AX877828 CAE89895.1 AX886023 CAF00161.1 NM_006100 NP_006091.1	Q9Y274	
α -2,6-sialyltransferase (ST6Gal II ; KIAA1877)	<i>Homo sapiens</i>	n.d.	BC008680 AAH08680.1 AB058780 BAB47506.1 AB059555 BAC24793.1 AJ512141 CAD54408.1 AX795193 CAE48260.1 AX795193 CAE48261.1 NM_032528 NP_115917.1	Q86Y44 Q8IUG7 Q96HE4 Q96JF0	
α -2,6-sialyltransferase (ST6GALNAC III)	<i>Homo sapiens</i>	n.d.	BC059363 AAH59363.1 AY358540 AAQ88904.1 AK091215 BAC03611.1 AJ507291 CAD45371.1 NM_152996 NP_694541.1	Q8N259 Q8NDV1	
α -2,6-sialyltransferase (ST6GalNAc V)	<i>Homo sapiens</i>	n.d.	BC001201 AAH01201.1 AK056241 BAB71127.1 AL035409 CAB72344.1 AJ507292 CAD45372.1 NM_030965 NP_112227.1	Q9BVH7	
α -2,6-sialyltransferase (SThM) ST6GalNAc II	<i>Homo sapiens</i>	2.4.99.-	U14550 AAA52228.1 BC040455 AAH40455.1 AJ251053 CAB61434.1 NM_006456 NP_006447.1	Q9UJ37 Q12971	
α -2,6-sialyltransferase ST6Gal I	<i>Homo sapiens</i>	2.4.99.1	BC031476 AAH31476.1 BC040009 AAH40009.1 A17362 CAA01327.1 A23699 CAA01686.1 X17247 CAA35111.1 X54363 CAA38246.1 X62822 CAA44634.1 NM_003032 NP_003023.1 NM_173216 NP_775323.1	P15907	
α -2,6-sialyltransferase ST6GalNAc I	<i>Homo sapiens</i>	2.4.99.3	BC022462 AAH22462.1 AY096001 AAM22800.1 AY358918 AAQ89277.1 AK000113 BAA90953.1 Y11339 CAA72179.2 NM_018414 NP_060884.1	Q8TBJ6 Q9NSC7 Q9NXQ7	
α -2,8- polysialyltransferase ST8Sia IV	<i>Homo sapiens</i>	2.4.99.-	L41680 AAC41775.1 BC027866 AAH27866.1 BC053657 AAH53657.1 NM_005668 NP_005659.1	Q8N1F4 Q92187 Q92693	
α -2,8-sialyltransferase (GD3 synthase) ST8Sia I	<i>Homo sapiens</i>	2.4.99.8	L32867 AAA62366.1 L43494 AAC37586.1 BC046158 AAH46158.1 -AAQ53140.1 AY569975 AAS75783.1 D26360 BAA05391.1 X77922 CAA54891.1 NM_003034 NP_003025.1	Q86X71 Q92185 Q93064	
α -2,8-sialyltransferase	<i>Homo sapiens</i>	2.4.99.-	L29556 AAA36613.1	Q92186	

FIGURE 1E

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
ST8Sia II			U82762 AAB51242.1 U33551 AAC24458.1 BC069584 AAH69584.1 NM_006011 NP_006002.1	Q92470 Q92746	
α -2,8-sialyltransferase ST8Sia III	<i>Homo sapiens</i>	2.4.99.-	AF004668 AAB87642.1 AF003092 AAC15901.2 NM_015879 NP_056963.1	Q43173 Q9NS41	
α -2,8-sialyltransferase ST8Sia V	<i>Homo sapiens</i>	2.4.99.-	U91641 AAC51727.1 CR457037 CAG33318.1 NM_013305 NP_037437.1	O15466	
ENSP00000020221 (fragment)		n.d.	AC023295 -		
lactosylceramide α -2,3- sialyltransferase (ST3Gal V)	<i>Homo sapiens</i>	2.4.99.9	AF105026 AAD14634.1 AF119415 AAF66146.1 BC065936 AAH65936.1 AY152815 AAO16866.1 AAP65066 AAP65066.1 AY359105 AAQ89463.1 AB018356 BAA33950.1 AX876536 CAE89320.1 NM_003896 NP_003887.2	Q9UNP4 O94902	
<i>N</i> -acetylgalactosaminide α -2,6-sialyltransferase (ST6GalNAc VI)	<i>Homo sapiens</i>	2.4.99.-	BC006564 AAH06564.1 BC007802 AAH07802.1 BC016299 AAH16299.1 AY358672 AAQ89035.1 AB035173 BAA87035.1 AK023900 BAB14715.1 AJ507293 CAD45373.1 AX880950 CAE91145.1 CR457318 CAG33599.1 NM_013443 NP_038471.2	Q969X2 Q9H8A2 Q9ULB8	
<i>N</i> -acetylgalactosaminide α -2,6-sialyltransferase IV (ST6GalNAc IV)	<i>Homo sapiens</i>	2.4.99.-	AF127142 AAF00102.1 BC036705 AAH36705.1 - AAP63349.1 AB035172 BAA87034.1 AK000600 BAA91281.1 Y17461 CAB44354.1 AJ271734 CAC07404.1 AX061620 CAC24981.1 AX068265 CAC27250.1 AX969252 CAF14360.1 NM_014403 NP_055218.3 NM_175039 NP_778204.1	Q9H4F1 Q9NWU6 Q9UKU1 Q9ULB9 Q9Y3G3 Q9Y3G4	
ST8SIA-VI (fragment)	<i>Homo sapiens</i>	n.d.	AJ621583 CAF21722.1 XM_291725 XP_291725.2		
unnamed protein product	<i>Homo sapiens</i>	n.d.	AK021929 BAB13940.1 AX881696 CAE91353.1	Q9HAA9	
Gal β -1,3/4-GlcNAc α - 2,3-sialyltransferase (ST3Gal III)	<i>Mesocricetus auratus</i>	2.4.99.6	AJ245699 CAB53394.1	Q9QXF6	

FIGURE 1F

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
Gal β -1,3/4-GlcNAc α -2,3-sialyltransferase (ST3Gal IV)	<i>Mesocricetus auratus</i>	2.4.99.6	AJ245700 CAB53395.1	Q9QXF5	
GD3 synthase (fragment)	<i>Mesocricetus auratus</i>	n.d.	AF141657 AAD33879.1	Q9WUL1	
ST8Sia I polysialyltransferase (ST8Sia IV)	<i>Mesocricetus auratus</i>	2.4.99.-	AJ245701 CAB53396.1	Q9QXF4	
α -2,3-sialyltransferase ST3Gal I	<i>St3gal1 Mus musculus</i>	2.4.99.4	AF214028 AAF60973.1 AK031344 BAC27356.1 AK078469 BAC37290.1 X73523 CAA51919.1 NM_009177 NP_033203.1	P54751 Q11202 Q9JL30	
α -2,3-sialyltransferase ST3Gal II	<i>St3gal2 Mus musculus</i>	2.4.99.4	BC015264 AAH15264.1 BC066064 AAH66064.1 AK034554 BAC28752.1 AK034863 BAC28859.1 AK053827 BAC35543.1 X76989 CAA54294.1 NM_009179 NP_033205.1 NM_178048 NP_835149.1	Q11204 Q8BPL0 Q8BSA0 Q8BSE9 Q91WH6	
α -2,3-sialyltransferase ST3Gal III	<i>St3gal3 Mus musculus</i>	2.4.99.-	BC006710 AAH06710.1 AK005053 BAB23779.1 AK013016 BAB28598.1 X84234 CAA59013.1 NM_009176 NP_033202.2	P97325 Q922X5 Q9CZ48 Q9DBB6	
α -2,3-sialyltransferase ST3Gal IV	<i>St3gal4 Mus musculus</i>	2.4.99.4	BC011121 AAH11121.1 BC050773 AAH50773.1 D28941 BAA06068.1 AK008543 BAB25732.1 AB061305 BAB47508.1 X95809 CAA65076.1 NM_009178 NP_033204.2	P97354 Q61325 Q91Y74 Q921R5 Q9CVE8	
α -2,3-sialyltransferase ST3Gal VI	<i>St3gal6 Mus musculus</i>	2.4.99.4	AF119390 AAD39130.1 BC052338 AAH52338.1 AB063326 BAB79494.1 AK033562 BAC28360.1 AK041173 BAC30851.1 NM_018784 NP_061254	Q80UR7 Q8BLV1 Q8VIB3 Q9WVG2	
α -2,6-sialyltransferase ST6GalNAc II	<i>St6galnac2 Mus musculus</i>	2.4.99.-	NM_009180 6677963 BC010208 AAH10208.1 AB027198 BAB00637.1 AK004613 BAB23410.1 X93999 CAA63821.1 X94000 CAA63822.1 NM_009180 NP_033206.2	P70277 Q9DC24 Q9JJM5	
α -2,6-sialyltransferase ST6Gal I	<i>St6gal1 Mus musculus</i>	2.4.99.1	-AAE68031.1 BC027833 AAH27833.1 D16106 BAA03680.1 AK034768 BAC28828.1 AK084124 BAC39120.1 NM_145933 NP_666045.1	Q64685 Q8BM62 Q8K1L1	
α -2,6-sialyltransferase ST6Gal II	<i>St6gal2 Mus musculus</i>	n.d.	AK082566 BAC38534.1 AB095093 BAC87752.1 AK129462 BAC98272.1 NM_172829 NP_766417.1	Q8BUU4	
α -2,6-sialyltransferase ST6GalNAc I	<i>St6galnac1 Mus musculus</i>	2.4.99.3	Y11274 CAA72137.1 NM_011371 NP_035501.1	Q9QZ39 Q9JJP5	
α -2,6-sialyltransferase ST6GalNAc III	<i>St6galnac3 Mus musculus</i>	n.d.	BC058387 AAH58387.1 AK034804 BAC28836.1 Y11342 CAA72181.2 Y11343 CAB95031.1 NM_011372 NP_035502	Q9WUV2 Q9JHP5	
α -2,6-sialyltransferase ST6GalNAc IV	<i>St6galnac4 Mus musculus</i>	2.4.99.7	BC056451 AAH56451.1 AK085730 BAC39523.1 AJ007310 CAA07446.1 Y15779 CAB43507.1	Q8C3J2 Q9JHP2 Q9R2B6 O88725	

FIGURE 1G

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
			Y15780 CAB43514.1	Q9JHP0	
			Y19055 CAB93946.1	Q9QUP9	
			Y19057 CAB93948.1	Q9R2B5	
			NM_011373 NP_035503.1		
α -2,8-sialyltransferase (GD3 synthase) ST8Sia I	<i>St8sia1</i>	<i>Mus musculus</i>	2.4.99.8	L38677 AAA91869.1	Q64468
			BC024821 AAH24821.1	Q64687	
			AK046188 BAC32625.1	Q8BL76	
			AK052444 BAC34994.1	Q8BW10	
			X84235 CAA59014.1	Q8K1C1	
			AJ401102 CAC20706.1	Q9EPK0	
			NM_011374 NP_035504.1		
α -2,8-sialyltransferase (ST8Sia VI)	<i>St8sia6</i>	<i>Mus musculus</i>	n.d.	AB059554 BAC01265.1	Q8BI43
			AK085105 BAC39367.1	Q8K4T1	
			NM_145838 NP_665837.1		
α -2,8-sialyltransferase ST8Sia II	<i>St8sia2</i>	<i>Mus musculus</i>	2.4.99.-	X83562 CAA58548.1	O35696
			X99646 CAA67965.1		
			X99647 CAA67965.1		
			X99648 CAA67965.1		
			X99649 CAA67965.1		
			X99650 CAA67965.1		
			X99651 CAA67965.1		
			NM_009181 NP_033207.1		
α -2,8-sialyltransferase ST8Sia IV	<i>St8sia4</i>	<i>Mus musculus</i>	2.4.99.8	BC060112 AAH60112.1	Q64692
			AK003690 BAB22941.1	Q8BY70	
			AK041723 BAC31044.1		
			AJ223956 CAA11685.1		
			X86000 CAA59992.1		
			Y09484 CAA70692.1		
			NM_009183 NP_033209.1		
α -2,8-sialyltransferase ST8Sia V	<i>St8sia5</i>	<i>Mus musculus</i>	2.4.99.-	BC034855 AAH34855.1	P70126
			AK078670 BAC37354.1	P70127	
			X98014 CAA66642.1	P70128	
			X98014 CAA66643.1	Q8BJW0	
			X98014 CAA66644.1	Q8JZQ3	
			NM_013666 NP_038694.1		
			NM_153124 NP_694764.1		
			NM_177416 NP_803135.1		
α -2,8-sialyltransferase ST8Sia III	<i>St8sia3</i>	<i>Mus musculus</i>	2.4.99.-	BC075645 AAH75645.1	Q64689
			AK015874 BAB30012.1	Q9CUJ6	
			X80502 CAA56665.1		
			NM_009182 NP_033208.1		
GD1 synthase (ST6GalNAc V)	<i>St6galnac5</i>	<i>Mus musculus</i>	n.d.	BC055737 AAH55737.1	Q8CAM7
			AB030836 BAA85747.1	Q8CBX1	
			AB028840 BAA89292.1	Q9QYJ1	
			AK034387 BAC28693.1	Q9R0K6	
			AK038434 BAC29997.1		
			AK042683 BAC31331.1		
			NM_012028 NP_036158.2		
GM3 synthase (α -2,3- sialyltransferase) ST3Gal V	<i>St3gal5</i>	<i>Mus musculus</i>	2.4.99.9	AF119416 AAF66147.1	Q88829
			- AAP65063.1	Q9CZ65	
			AB018048 BAA33491.1	Q9QWF9	
			AB013302 BAA76467.1		
			AK012961 BAB28571.1		
			Y15003 CAA75235.1		
			NM_011375 NP_035505.1		
<i>N</i> -acetylgalactosaminide α -2,6-sialyltransferase (ST6GalNAc VI)	<i>St6galnac6</i>	<i>Mus musculus</i>	2.4.99.-	BC036985 AAH36985.1	Q8CDC3
			AB035174 BAA87036.1	Q8JZW3	
			AB035123 BAA95940.1	Q9JM95	
			AK030648 BAC27064.1	Q9R0G9	
			NM_016973 NP_058669.1		
M138L	<i>Myxoma virus</i>	n.d.	U46578 AAD00069.1		
			AF170726 AAE61323.1		
			NC_001132 AAE61326.1		
			AAF15026.1		
			NP_051852.1		
α -2,3-sialyltransferase	<i>Oncorhynchus</i>	n.d.	AJ585760 CAE51384.1		

FIGURE 1H

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
(ST3Gal-I)	<i>mykiss</i>				
α -2,6-sialyltransferase (Siat1)	<i>Oncorhynchus mykiss</i>	n.d.	AJ620649 CAF05848.1		
α -2,8-polysialyltransferase IV (ST8Sia IV)	<i>Oncorhynchus mykiss</i>	n.d.	AB094402 BAC77411.1	Q7T2X5	
GalNAc α -2,6-sialyltransferase (RtST6GalNAc)	<i>Oncorhynchus mykiss</i>	n.d.	AB097943 BAC77520.1	Q7T2X4	
α -2,3-sialyltransferase ST3Gal IV	<i>Oryctolagus cuniculus</i>	2.4.99.-	AF121967 AAF28871.1	Q9N257	
OJ1217_F02.7	<i>Oryza sativa</i> (japonica cultivar-group)	n.d.	AP004084 BAD07616.1		
OSJNBa0043L24.2 or OSJNBb0002J11.9	<i>Oryza sativa</i> (japonica cultivar-group)	n.d.	AL731626 CAD41185.1 AL662969 CAE04714.1		
P0683f02.18 or P0489B03.1	<i>Oryza sativa</i> (japonica cultivar-group)	n.d.	AP003289 BAB63715.1 AP003794 BAB90552.1		
α -2,6-sialyltransferase ST6GalNAc V (Siat7E) (fragment)	<i>Oryzias latipes</i>	n.d.	AJ646876 CAG26705.1		
α -2,3-sialyltransferase ST3Gal I (Siat4)	<i>Pan troglodytes</i>	n.d.	AJ744803 CAG32839.1		
α -2,3-sialyltransferase ST3Gal II (Siat5)	<i>Pan troglodytes</i>	n.d.	AJ744804 CAG32840.1		
α -2,3-sialyltransferase ST3Gal III (Siat6)	<i>Pan troglodytes</i>	n.d.	AJ626819 CAF25177.1		
α -2,3-sialyltransferase ST3Gal IV (Siat4c)	<i>Pan troglodytes</i>	n.d.	AJ626824 CAF25182.1		
α -2,3-sialyltransferase ST3Gal VI (Siat10)	<i>Pan troglodytes</i>	n.d.	AJ744808 CAG32844.1		
α -2,6-sialyltransferase (Sia7A)	<i>Pan troglodytes</i>	n.d.	AJ748740 CAG38615.1		
α -2,6-sialyltransferase (Sia7B)	<i>Pan troglodytes</i>	n.d.	AJ748741 CAG38616.1		
α -2,6-sialyltransferase ST6GalNAc III (Siat7C)	<i>Pan troglodytes</i>	n.d.	AJ634454 CAG25676.1		
α -2,6-sialyltransferase ST6GalNAc IV (Siat7D) (fragment)	<i>Pan troglodytes</i>	n.d.	AJ646870 CAG26699.1		
α -2,6-sialyltransferase ST6GalNAc V (Siat7E)	<i>Pan troglodytes</i>	n.d.	AJ646875 CAG26704.1		
α -2,6-sialyltransferase ST6GalNAc VI (Siat7F) (fragment)	<i>Pan troglodytes</i>	n.d.	AJ646882 CAG26711.1		
α -2,8-sialyltransferase 8A (Siat8A)	<i>Pan troglodytes</i>	2.4.99.8	AJ697658 CAG26896.1		
α -2,8-sialyltransferase 8B (Siat8B)	<i>Pan troglodytes</i>	n.d.	AJ697659 CAG26897.1		
α -2,8-sialyltransferase 8C (Siat8C)	<i>Pan troglodytes</i>	n.d.	AJ697660 CAG26898.1		
α -2,8-sialyltransferase 8D (Siat8D)	<i>Pan troglodytes</i>	n.d.	AJ697661 CAG26899.1		
α -2,8-sialyltransferase 8E (Siat8E)	<i>Pan troglodytes</i>	n.d.	AJ697662 CAG26900.1		
α -2,8-sialyltransferase 8F (Siat8F)	<i>Pan troglodytes</i>	n.d.	AJ697663 CAG26901.1		
β -galactosamide α -2,6-sialyltransferase I (ST6Gal I; Siat1)	<i>Pan troglodytes</i>	2.4.99.1	AJ627624 CAF29492.1		
β -galactosamide α -2,6-sialyltransferase II (ST6Gal II)	<i>Pan troglodytes</i>	n.d.	AJ627625 CAF29493.1		
GM3 synthase ST3Gal V	<i>Pan troglodytes</i>	n.d.	AJ744807 CAG32843.1		

FIGURE 11

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
(Siat9)					
S138L	<i>Rabbit fibroma virus Kasza</i>	n.d.	NC_001266 NP_052025		
α -2,3-sialyltransferase ST3Gal III	<i>Rattus norvegicus</i>	2.4.99.6	M97754 AAA42146.1 NM_031697 NP_113885.1	Q02734	
α -2,3-sialyltransferase ST3Gal IV (Siat4c)	<i>Rattus norvegicus</i>	n.d.	AJ626825 CAF25183.1		
α -2,3-sialyltransferase ST3Gal VI	<i>Rattus norvegicus</i>	n.d.	AJ626743 CAF25053.1		
α -2,6-sialyltransferase ST3Gal II	<i>Rattus norvegicus</i>	2.4.99.-	X76988 CAA54293.1 NM_031695 NP_113883.1	Q11205	
α -2,6-sialyltransferase ST6Gal I	<i>Rattus norvegicus</i>	2.4.99.1	M18769 AAA41196.1 M83143 AAB07233.1	P13721	
α -2,6-sialyltransferase ST6GalNAc I (Siat7A)	<i>Rattus norvegicus</i>	n.d.	AJ634458 CAG25684.1		
α -2,6-sialyltransferase ST6GalNAc II (Siat7B)	<i>Rattus norvegicus</i>	n.d.	AJ634457 CAG25679.1		
α -2,6-sialyltransferase ST6GalNAc III	<i>Rattus norvegicus</i>	2.4.99.-	L29554 AAC42086.1 BC072501 AAH72501.1 NM_019123 NP_061996.1	Q64686	
α -2,6-sialyltransferase ST6GalNAc IV (Siat7D) (fragment)	<i>Rattus norvegicus</i>	n.d.	AJ646871 CAG26700.1		
α -2,6-sialyltransferase ST6GalNAc V (Siat7E)	<i>Rattus norvegicus</i>	n.d.	AJ646872 CAG26701.1		
α -2,6-sialyltransferase ST6GalNAc VI (Siat7F) (fragment)	<i>Rattus norvegicus</i>	n.d.	AJ646881 CAG26710.1		
α -2,8-sialyltransferase (GD3 synthase) ST8Sia I	<i>Rattus norvegicus</i>	2.4.99.-	U53883 AAC27541.1 D45255 BAA08213.1	P70554 P97713	
α -2,8-sialyltransferase (SIAT8E)	<i>Rattus norvegicus</i>	n.d.	AJ699422 CAG27884.1		
α -2,8-sialyltransferase (SIAT8F)	<i>Rattus norvegicus</i>	n.d.	AJ699423 CAG27885.1		
α -2,8-sialyltransferase ST8Sia II	<i>Rattus norvegicus</i>	2.4.99.-	L13445 AAA42147.1 NM_057156 NP_476497.1	Q07977 Q64688	
α -2,8-sialyltransferase ST8Sia III	<i>Rattus norvegicus</i>	2.4.99.-	U55938 AAB50061.1 NM_013029 NP_037161.1	P97877	
α -2,8-sialyltransferase ST8Sia IV	<i>Rattus norvegicus</i>	2.4.99.-	U90215 AAB49989.1	O08563	
β -galactosamide α -2,6-sialyltransferase II (ST6Gal II)	<i>Rattus norvegicus</i>	n.d.	AJ627626 CAF29494.1		
GM3 synthase ST3Gal V	<i>Rattus norvegicus</i>	n.d.	AB018049 BAA33492.1 NM_031337 NP_112627.1	O88830	
sialyltransferase ST3Gal-I (Siat4A)	<i>Rattus norvegicus</i>	n.d.	AJ748840 CAG44449.1		
α -2,3-sialyltransferase (St3Gal-II)	<i>Silurana tropicalis</i>	n.d.	AJ585763 CAE51387.1		
α -2,6-sialyltransferase (Siat7b)	<i>Silurana tropicalis</i>	n.d.	AJ620650 CAF05849.1		
α -2,6-sialyltransferase (St6galnac)	<i>Strongylocentrotus purpuratus</i>	n.d.	AJ699425 CAG27887.1		
α -2,3-sialyltransferase (ST3GAL-III)	<i>Sus scrofa</i>	n.d.	AJ585765 CAE51389.1		
α -2,3-sialyltransferase (ST3GAL-IV)	<i>Sus scrofa</i>	n.d.	AJ584674 CAE48299.1		
α -2,3-sialyltransferase ST3Gal I	<i>Sus scrofa</i>	2.4.99.4	M97753 AAA31125.1	Q02745	
α -2,6-sialyltransferase (fragment) ST6Gal I	<i>Sus scrofa</i>	2.4.99.1	AF136746 AAD33059.1	Q9XSG8	
β -galactosamide α -2,6-sialyltransferase (ST6GalNAc-V)	<i>Sus scrofa</i>	n.d.	AJ620948 CAF06585.2		
sialyltransferase (fragment) ST6Gal I	<i>sus scrofa</i>	n.d.	AF041031 AAC15633.1	O62717	

FIGURE 1J

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
ST6GALNAC-V	<i>Sus scrofa</i>	n.d.	AJ620948 CAF06585.1		
α -2,3-sialyltransferase (Siat5-r)	<i>Takifugu rubripes</i>	n.d.	AJ744805 CAG32841.1		
α -2,3-sialyltransferase ST3Gal I (Siat4)	<i>Takifugu rubripes</i>	n.d.	AJ626816 CAF25174.1		
α -2,3-sialyltransferase ST3Gal II (Siat5) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ626817 CAF25175.1		
α -2,3-sialyltransferase ST3Gal III (Siat6)	<i>Takifugu rubripes</i>	n.d.	AJ626818 CAF25176.1		
α -2,6-sialyltransferase ST6Gal I (Siat1)	<i>Takifugu rubripes</i>	n.d.	AJ744800 CAG32836.1		
α -2,6-sialyltransferase ST6GalNac II (Siat7B)	<i>Takifugu rubripes</i>	n.d.	AJ634460 CAG25681.1		
α -2,6-sialyltransferase ST6GalNac II B (Siat7B-related)	<i>Takifugu rubripes</i>	n.d.	AJ634461 CAG25682.1		
α -2,6-sialyltransferase ST6GalNac III (Siat7C) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ634456 CAG25678.1		
α -2,6-sialyltransferase ST6GalNac IV (Siat7D) (fragment)	<i>Takifugu rubripes</i>	2.4.99.3	Y17466 CAB44338.1 AJ646869 CAG26698.1	Q9W6U6	
α -2,6-sialyltransferase ST6GalNac V (Siat7E) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ646873 CAG26702.1		
α -2,6-sialyltransferase ST6GalNac VI (Siat7F) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ646880 CAG26709.1		
α -2,8-sialyltransferase ST8Sia I (Siat 8A) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ715534 CAG29373.1		
α -2,8-sialyltransferase ST8Sia II (Siat 8B) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ715538 CAG29377.1		
α -2,8-sialyltransferase ST8Sia III (Siat 8C) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ715541 CAG29380.1		
α -2,8-sialyltransferase ST8Sia IIIr (Siat 8Cr)	<i>Takifugu rubripes</i>	n.d.	AJ715542 CAG29381.1		
α -2,8-sialyltransferase ST8Sia V (Siat 8E) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ715547 CAG29386.1		
α -2,8-sialyltransferase ST8Sia VI (Siat 8F) (fragment)	<i>Takifugu rubripes</i>	n.d.	AJ715549 CAG29388.1		
α -2,8-sialyltransferase ST8Sia VIr (Siat 8Fr)	<i>Takifugu rubripes</i>	n.d.	AJ715550 CAG29389.1		
α -2,3-sialyltransferase (Siat5-r)	<i>Tetraodon nigroviridis</i>	n.d.	AJ744806 CAG32842.1		
α -2,3-sialyltransferase ST3Gal I (Siat4)	<i>Tetraodon nigroviridis</i>	n.d.	AJ744802 CAG32838.1		
α -2,3-sialyltransferase ST3Gal III (Siat6)	<i>Tetraodon nigroviridis</i>	n.d.	AJ626822 CAF25180.1		
α -2,6-sialyltransferase ST6GalNac II (Siat7B)	<i>Tetraodon nigroviridis</i>	n.d.	AJ634462 CAG25683.1		
α -2,6-sialyltransferase ST6GalNac V (Siat7E) (fragment)	<i>Tetraodon nigroviridis</i>	n.d.	AJ646879 CAG26708.1		
α -2,8-sialyltransferase ST8Sia I (Siat 8A) (fragment)	<i>Tetraodon nigroviridis</i>	n.d.	AJ715536 CAG29375.1		
α -2,8-sialyltransferase ST8Sia II (Siat 8B) (fragment)	<i>Tetraodon nigroviridis</i>	n.d.	AJ715537 CAG29376.1		
α -2,8-sialyltransferase	<i>Tetraodon</i>	n.d.	AJ715539 CAG29378.1		

FIGURE 1K

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
ST8Sia III (Siat 8C) (fragment)	<i>nigroviridis</i>				
α -2,8-sialyltransferase ST8Sia IIIr (Siat 8Cr) (fragment)	<i>Tetraodon nigroviridis</i>	n.d.	AJ715540 CAG29379.1		
α -2,8-sialyltransferase ST8Sia V (Siat 8E) (fragment)	<i>Tetraodon nigroviridis</i>	n.d.	AJ715548 CAG29387.1		
α -2,3-sialyltransferase (St3Gal-II)	<i>Xenopus laevis</i>	n.d.	AJ585762 CAE51386.1		
α -2,3-sialyltransferase (St3Gal-VI)	<i>Xenopus laevis</i>	n.d.	AJ585766 CAE51390.1		
α -2,3-sialyltransferase St3Gal-III (Siat6)	<i>Xenopus laevis</i>	n.d.	AJ585764 CAE51388.1 AJ626823 CAF25181.1		
α -2,8-polysialyltransferase	<i>Xenopus laevis</i>	2.4.99.-	AB007468 BAA32617.1	O93234	
α -2,8-sialyltransferase ST8Sia-I (Siat8A;GD3 synthase)	<i>Xenopus laevis</i>	n.d.	AY272056 AAQ16162.1 AY272057 AAQ16163.1 AJ704562 CAG28695.1		
Unknown (protein for MGC:81265)	<i>Xenopus laevis</i>	n.d.	BC068760 AAH68760.1		
α -2,3-sialyltransferase (3Gal-VI)	<i>Xenopus tropicalis</i>	n.d.	AJ626744 CAF25054.1		
α -2,3-sialyltransferase (Siat4c)	<i>Xenopus tropicalis</i>	n.d.	AJ622908 CAF22058.1		
α -2,6-sialyltransferase ST6GalNAc V (Siat7E) (fragment)	<i>Xenopus tropicalis</i>	n.d.	AJ646878 CAG26707.1		
α -2,8-sialyltransferase ST8Sia III (Siat 8C) (fragment)	<i>Xenopus tropicalis</i>	n.d.	AJ715544 CAG29383.1		
β -galactosamide α -2,6- sialyltransferase II (ST6Gal II)	<i>Xenopus tropicalis</i>	n.d.	AJ627628 CAF29496.1		
sialyltransferase St8Sial	<i>Xenopus tropicalis</i>	n.d.	AY652775 AAT67042		
poly- α -2,8-sialosyl sialyltransferase (NeuS)	<i>Escherichia coli</i> K1	2.4.-.-	M76370 AAA24213.1 X60598 CAA43053.1	Q57269	
polysialyltransferase	<i>Escherichia coli</i> K92	2.4.-.-	M88479 AAA24215.1	Q47404	
α -2,8 polysialyltransferase SiaD SynE	<i>Neisseria meningitidis</i> B1940	2.4.-.-	M95053 AAA20478.1 X78068 CAA54985.1	Q51281 Q51145	
	<i>Neisseria meningitidis</i> FAM18	n.d.	U75650 AAB53842.1	O06435	
polysialyltransferase (SiaD)(fragment)	<i>Neisseria meningitidis</i> M1019	n.d.	AY234192 AAO85290.1		
SiaD (fragment)	<i>Neisseria meningitidis</i> M209	n.d.	AY281046 AAP34769.1		
SiaD (fragment)	<i>Neisseria meningitidis</i> M3045	n.d.	AY281044 AAP34767.1		
polysialyltransferase (SiaD)(fragment)	<i>Neisseria meningitidis</i> M3315	n.d.	AY234191 AAO85289.1		
SiaD (fragment)	<i>Neisseria meningitidis</i> M3515	n.d.	AY281047 AAP34770.1		
polysialyltransferase (SiaD)(fragment)	<i>Neisseria meningitidis</i> M4211	n.d.	AY234190 AAO85288.1		
SiaD (fragment)	<i>Neisseria meningitidis</i> M4642	n.d.	AY281048 AAP34771.1		
polysialyltransferase (SiaD)(fragment)	<i>Neisseria meningitidis</i> M5177	n.d.	AY234193 AAO85291.1		
SiaD	<i>Neisseria meningitidis</i> M5178	n.d.	AY281043 AAP34766.1		
SiaD (fragment)	<i>Neisseria meningitidis</i> M980	n.d.	AY281045 AAP34768.1		
NMB0067	<i>Neisseria meningitidis</i> MC58	n.d.	NC_003112 NP_273131		

FIGURE 1L

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
Lst	<i>Aeromonas punctata</i> Sch3	n.d.	AF126256 AAS66624.1		
ORF2	<i>Haemophilus influenzae</i> A2	n.d.	M94855 AAA24979.1		
HI1699	<i>Haemophilus influenzae</i> Rd	n.d.	U32842 AAC23345.1 NC_000907 NP_439841.1	Q48211	
α -2,3-sialyltransferase	<i>Neisseria gonorrhoeae</i> F62	2.4.99.4	U60664 AAC44539.1 AAE67205.1	P72074	
α -2,3-sialyltransferase	<i>Neisseria meningitidis</i> 126E, NRCC 4010	2.4.99.4	U60662 AAC44544.2		
α -2,3-sialyltransferase	<i>Neisseria meningitidis</i> 406Y, NRCC 4030	2.4.99.4	U60661 AAC44543.1		
α -2,3-sialyltransferase (NMB0922)	<i>Neisseria meningitidis</i> MC58	2.4.99.4	U60660 AAC44541.1 AE002443 AAF41330.1 NC_003112 NP_273962.1	P72097	
NMA1118	<i>Neisseria meningitidis</i> Z2491	n.d.	AL162755 CAB84380.1 NC_003116 NP_283887.1	Q9JUV5	
PM0508	<i>Pasteurella multocida</i> PM70	n.d.	AE006086 AAK02592.1 NC_002663 NP_245445.1	Q9CNC4	
WaaH	<i>Salmonella enterica</i> SARB25	n.d.	AF519787 AAM82550.1	Q8KS93	
WaaH	<i>Salmonella enterica</i> SARB3	n.d.	AF519788 AAM82551.1	Q8KS92	
WaaH	<i>Salmonella enterica</i> SARB39	n.d.	AF519789 AAM82552.1		
WaaH	<i>Salmonella enterica</i> SARB53	n.d.	AF519790 AAM82553.1		
WaaH	<i>Salmonella enterica</i> SARB57	n.d.	AF519791 AAM82554.1	Q8KS91	
WaaH	<i>Salmonella enterica</i> SARB71	n.d.	AF519793 AAM82556.1	Q8KS89	
WaaH	<i>Salmonella enterica</i> SARB8	n.d.	AF519792 AAM82555.1	Q8KS90	
WaaH	<i>Salmonella enterica</i> SARC10V	n.d.	AF519779 AAM88840.1	Q8KS99	
WaaH (fragment)	<i>Salmonella enterica</i> SARC12	n.d.	AF519781 AAM88842.1		
WaaH (fragment)	<i>Salmonella enterica</i> SARC13I	n.d.	AF519782 AAM88843.1	Q8KS98	
WaaH (fragment)	<i>Salmonella enterica</i> SARC14I	n.d.	AF519783 AAM88844.1	Q8KS97	
WaaH	<i>Salmonella enterica</i> SARC15II	n.d.	AF519784 AAM88845.1	Q8KS96	
WaaH	<i>Salmonella enterica</i> SARC16II	n.d.	AF519785 AAM88846.1	Q8KS95	


FIGURE 1M

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
WaaH (fragment)	<i>Salmonella enterica</i> SARC3I	n.d.	AF519772 AAM88834.1	Q8KSA4	
WaaH (fragment)	<i>Salmonella enterica</i> SARC4I	n.d.	AF519773 AAM88835.1	Q8KSA3	
WaaH	<i>Salmonella enterica</i> SARC5IIa	n.d.	AF519774 AAM88836.1		
WaaH	<i>Salmonella enterica</i> SARC6IIa	n.d.	AF519775 AAM88837.1	Q8KSA2	
WaaH	<i>Salmonella enterica</i> SARC8	n.d.	AF519777 AAM88838.1	Q8KSA1	
WaaH	<i>Salmonella enterica</i> SARC9V	n.d.	AF519778 AAM88839.1	Q8KSA0	
UDP-glucose : α -1,2-glucosyltransferase (WaaH)	<i>Salmonella enterica</i> subsp. <i>arizonae</i> SARC 5	2.4.1.-	AF511116 AAM48166.1		
bifunctional α -2,3/-2,8-sialyltransferase (Cst-II)	<i>Campylobacter jejuni</i> ATCC 43449	n.d.	AF401529 AAL06004.1	Q93CZ5	
Cst	<i>Campylobacter jejuni</i> 81-176	n.d.	AF305571 AAL09368.1		
α -2,3-sialyltransferase (Cst-III)	<i>Campylobacter jejuni</i> ATCC 43429	2.4.99.-	AY044156 AAK73183.1		
α -2,3-sialyltransferase (Cst-III)	<i>Campylobacter jejuni</i> ATCC 43430	2.4.99.-	AF400047 AAK85419.1		
α -2,3-sialyltransferase (Cst-II)	<i>Campylobacter jejuni</i> ATCC 43432	2.4.99.-	AF215659 AAG43979.1	Q9F0M9	
α -2,3/8-sialyltransferase (CstII)	<i>Campylobacter jejuni</i> ATCC 43438	n.d.	AF400048 AAK91725.1	Q93MQ0	
α -2,3-sialyltransferase cst-II	<i>Campylobacter jejuni</i> ATCC 43446	2.4.99.-	AF167344 AAF34137.1		
α -2,3-sialyltransferase (Cst-II)	<i>Campylobacter jejuni</i> ATCC 43456	2.4.99.-	AF401528 AAL05990.1	Q93D05	
α -2,3/- α -2,8-sialyltransferase (CstII)	<i>Campylobacter jejuni</i> ATCC 43460	2.4.99.-	AY044868 AAK96001.1	Q938X6	
α -2,3/8-sialyltransferase (Cst-II)	<i>Campylobacter jejuni</i> ATCC 700297	n.d.	AF216647 AAL36462.1		
ORF	<i>Campylobacter jejuni</i> GB11	n.d.	AY422197 AAR82875.1		
α -2,3-sialyltransferase cstIII	<i>Campylobacter jejuni</i> MSC57360	2.4.99.-	AF195055 AAG29922.1		
α -2,3-sialyltransferase cstII	<i>Campylobacter jejuni</i> NCTC 11168	2.4.99.-	AL139077 CAB73395.1	Q9PNF4	
CJ1140			NC_002163 NP_282288.1		
α -2,3/- α -2,8-sialyltransferase II (cstII)	<i>Campylobacter jejuni</i> O:10	n.d.	-AAO96669.1		
α -2,3/- α -2,8-sialyltransferase II (CstII)	<i>Campylobacter jejuni</i> O:19	n.d.	AX934427 CAF04167.1		
α -2,3/- α -2,8-sialyltransferase II (CstII)	<i>Campylobacter jejuni</i> O:36	n.d.	AX934431 CAF04169.1		
α -2,3/- α -2,8-sialyltransferase II (CstII)	<i>Campylobacter jejuni</i> O:36	n.d.	AX934436 CAF04171.1		
α -2,3/- α -2,8-sialyltransferase II (CstII)	<i>Campylobacter jejuni</i> O:4	n.d.	AX934434 CAF04170.1		
α -2,3/- α -2,8-sialyltransferase II (CstII)	<i>Campylobacter jejuni</i> O:41	n.d.	-AAO96670.1		
			-AAT17967.1		
			AX934429 CAF04168.1		
α -2,3-sialyltransferase cst-I	<i>Campylobacter jejuni</i> OH4384	2.4.99.-	AF130466 AAF13495.1	Q9RGF1	
			-AAS36261.1		
bifunctional α -2,3/-2,8-sialyltransferase (Cst-II)	<i>Campylobacter jejuni</i> OH4384	2.4.99.-	AF130984 AAF31771.1		1RO7C
			AX934425 CAF04166.1		1RO8A

FIGURE 1N

Protein	Organism	EC#	GenBank / GenPept	SwissProt	PDB / 3D
HI0352 (fragment)	<i>Haemophilus influenzae</i>	n.d.	U32720 AAC22013.1	P24324	
	<i>Rd</i>		X57315 CAA40567.1		
			NC_000907 NP_438516.1		
PM1174	<i>Pasteurella multocida</i>	n.d.	AE006157 AAK03258.1	Q9CLP3	
	<i>PM70</i>		NC_002663 NP_246111.1		
Sequence 10 from patent US 6503744	<i>Unknown.</i>	n.d.	-AAO96672.1		
Sequence 10 from patent US 6699705	<i>Unknown.</i>	n.d.	-AAT17969.1		
Sequence 12 from patent US 6699705	<i>Unknown.</i>	n.d.	-AAT17970.1		
Sequence 2 from patent US 6709834	<i>Unknown.</i>	n.d.	-AAT23232.1		
Sequence 3 from patent US 6503744	<i>Unknown.</i>	n.d.	-AAO96668.1		
Sequence 3 from patent US 6699705	<i>Unknown.</i>	n.d.	-AAT17965.1		
Sequence 34 from patent US 6503744	<i>Unknown.</i>	n.d.	-AAO96684.1		
Sequence 35 from patent US 6503744 (fragment)	<i>Unknown.</i>	n.d.	-AAO96685.1		
			-AAS36262.1		
Sequence 48 from patent US 6699705	<i>Unknown.</i>	n.d.	-AAT17988.1		
Sequence 5 from patent US 6699705	<i>Unknown.</i>	n.d.	-AAT17966.1		
Sequence 9 from patent US 6503744	<i>Unknown.</i>	n.d.	-AAO96671.1		

FIGURE 2



- a.** $AG^1-O-C(=O)-AANHP$, base; **b.** pyruvate, AS-Aldolase, buffer; **c.** synthetase, nucleotide phosphate; **d.** deprotecting reagent; **e.** activated PEG

NP = nucleotide phosphate; P = protecting group; PEG = poly(ethylene glycol) or methoxy-poly(ethylene glycol)

FIGURE 3




FIGURE 4




FIGURE 5

